<SEC-DOCUMENT>0001047469-18-004247.txt : 20180604
<SEC-HEADER>0001047469-18-004247.hdr.sgml : 20180604
<ACCEPTANCE-DATETIME>20180604160302
ACCESSION NUMBER:		0001047469-18-004247
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20180604
DATE AS OF CHANGE:		20180604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-225410
		FILM NUMBER:		18878112

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>a2235913zs-1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg49601_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As Filed with the Securities and Exchange Commission on June&nbsp;4, 2018  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>  </B></FONT><FONT SIZE=1><B>UNDER</B></FONT><FONT SIZE=1><B><BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware<BR> </B></FONT><FONT SIZE=1>(State or other jurisdiction of&nbsp;incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 2834</B></FONT><FONT SIZE=1><BR>
(Primary Standard Industrial&nbsp;Classification Code Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 26-3687168</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer&nbsp;Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>One Kendall Square<BR>
Bldg. 1400E, Suite B14202<BR>
Cambridge, Massachusetts 02139<BR>
(617)&nbsp;349-1971</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>


<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Jill C. Milne, Ph.D.<BR>
President and Chief Executive Officer<BR>
Catabasis Pharmaceuticals,&nbsp;Inc.<BR>
One Kendall Square<BR>
Bldg. 1400E, Suite B14202<BR>
Cambridge, Massachusetts 02139<BR>
(617)&nbsp;349-1971<BR>  </B></FONT><FONT SIZE=1>(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Rosemary G. Reilly, Esq.<BR>
WilmerHale<BR>
60 State Street<BR>
Boston, MA 02109<BR>
Telephone: (617)&nbsp;526-6000<BR>
Fax: (617)&nbsp;526-5000</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>John D. Hogoboom<BR>
Lowenstein Sandler&nbsp;LLP<BR>
1251 Avenue of the Americas<BR>
New York, NY 10020<BR>
Telephone: (212)&nbsp;262-6700<BR>
Fax: (212)&nbsp;262-7402<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=1>If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933, check the
following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="94pt" style="font-family:times;"></TD>
<TD WIDTH="13%" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="13%" style="font-family:times;"></TD>
<TD WIDTH="91pt" style="font-family:times;"></TD>
<TD WIDTH="13%" style="font-family:times;"></TD>
<TD WIDTH="111pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller reporting company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="72%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="78" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed&nbsp;Maximum<BR>
Aggregate Offering<BR>
Price(1)(2)(3)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Units, each Common Unit consisting of one share of common stock, par value $0.001 per share, and one warrant to purchase one share of common
stock(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>(i) Common stock included in the Common Units(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>(ii) Warrants included in the Common Units(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Pre-funded Units, each Pre-funded Unit consisting of one Pre-funded Warrant to purchase one share of common stock, and one Warrant to purchase one share of
common stock(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>(i) Pre-funded Warrants included in the Pre-funded Units(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>(ii) Warrants included in the Pre-funded Units(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Shares of common stock underlying Pre-funded Warrants included in the Pre-funded Units(3)(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Shares of common stock underlying Warrants included in the Common Units and the Pre-funded Units(3)(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-3pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$30,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$3,735</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Estimated
solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(o) under the Securities Act of 1933, as amended.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Pursuant
to Rule&nbsp;416(a) under the Securities Act of 1933, as amended, this registration statement shall also cover an indeterminate number of shares that may
be issued and resold resulting from stock splits, stock dividends or similar transactions.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
proposed maximum aggregate offering price of the Common Units proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the
offering price of any Pre-funded Units offered and sold in the offering, and the proposed maximum aggregate offering price of the Pre-funded Units to be sold in the offering will be reduced on a
dollar-for-dollar basis based on the offering price of any Common Units sold in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Units and Pre-funded Units
(including the common stock issuable upon exercise of the Warrants included in the Common Units and the Pre-funded Units and the Pre-funded Warrants included in the Pre-funded Units), if any, is
$30,000,0000.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Filing
fee included with the Common Units or Pre-funded Units, as applicable.  </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="30%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&nbsp;a further
amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration
Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=56446,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]BA49601A.;31',USER='HYUNG',CD=';4-JUN-2018;10:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT COLOR="#A6555F" SIZE=1><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until
the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy
these securities in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT COLOR="#A6555F" SIZE=2><B>SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018<BR>
PRELIMINARY PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g645187.jpg" ALT="GRAPHIC" WIDTH="189" HEIGHT="43">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Catabasis Pharmaceuticals,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$30,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Units, Each Consisting of One Share of Common Stock and a<BR>
Warrant to Purchase One Share of Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Pre-funded Units, Each Consisting of a Pre-funded Warrant to Purchase<BR>
One Share of Common Stock and a Warrant to Purchase One Share of<BR>
Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We are offering $30,000,000 of common units (each a "Common Unit"), each Common Unit consisting of one share of our common stock and a warrant to purchase one
share of our common stock at an exercise price per whole share of common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(each a "Warrant"). Each Warrant will be exercisable immediately and will expire five years from the
date of issuance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
are also offering to those purchasers, if any, whose purchase of Common Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties,
beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase,
if the purchaser so chooses, pre-funded units (each a "Pre-funded Unit") in lieu of Common Units that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or, at the
election of the purchaser, 9.99%) of our outstanding common stock. Each Pre-funded Unit will consist of a pre-funded warrant to purchase one share of our common stock at an exercise price of $0.01 per
share (each a "Pre-funded Warrant") and a Warrant. The purchase price of each Pre-funded Unit is equal to the price per Common Unit being sold to the public in this offering, minus $0.01. The
Pre-funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-funded Warrants are exercised in full. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
are also offering the shares of common stock that are issuable from time to time upon exercise of the Warrants and Pre-funded Warrants being offered by this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>For
each Pre-funded Unit we sell, the number of Common Units we are offering will be decreased on a one-for-one basis. Common Units and Pre-funded Units will not be issued or certificated. The shares
of common stock or Pre-funded Warrants, as the case may be, and the Warrants included in the Common Units or the Pre-funded Units, can only be purchased together in this offering, but the securities
contained in the Common Units or Pre-funded Units will be issued separately and will be immediately separable upon issuance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>There
is no established public trading market for the Warrants or the Pre-funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Warrants or the
Pre-funded Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants or the Pre-funded Warrants will be
limited. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
common stock is listed on the Nasdaq Global Market under the symbol "CATB." On June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, the last reported sale price per share of our common stock on the Nasdaq Global
Market was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The public offering price per Common Unit or Pre-funded Unit, as the case may be, will be determined between us, the underwriters and investors based on market
conditions
at the time of pricing, and may be at a discount to the current market price of our common stock. Therefore, the recent market price used throughout this prospectus may not be indicative of the final
offering price. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
are an "emerging growth company" under applicable Securities and Exchange Commission rules and are subject to reduced public company disclosure requirements. See "Summary&nbsp;&#150;
Implications of Being an Emerging Growth Company." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>You
should read this prospectus, together with additional information described under the headings "Incorporation of Certain Documents by Reference" and "Where You Can Find More Information,"
carefully before you invest in any of our securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT COLOR="#A6555F" SIZE=2><B>Investing in our securities involves risks. See "Risk Factors" beginning on page&nbsp;12 of this prospectus and in our Quarterly Report on Form&nbsp;10-Q
for the quarterly period ended March&nbsp;31, 2018, which is incorporated herein by reference.</B></FONT></P>

<P style="font-family:times;"><FONT COLOR="#A6555F" SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Common<BR>
Unit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Pre-funded<BR>
Unit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Price to the public</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Underwriting discount and commissions(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Proceeds to us (before expenses)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="22%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="22%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
refer you to "Underwriting" beginning on page&nbsp;40 for additional information regarding the compensation payable to the underwriters. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Delivery
of the securities offered hereby is expected to be made on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Oppenheimer&nbsp;&amp;&nbsp;Co.  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"> <FONT SIZE=2>
Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1046146,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]BC49601A.;66',USER='HYUNG',CD=';4-JUN-2018;10:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg49601_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG49601A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg49601_table_of_contents"> </A>
<BR></FONT><FONT SIZE=3><B>  TABLE OF CONTENTS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG49601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi49601_about_this_prospectus"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi49601_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca49601_prospectus_summary"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca49601_prospectus_summary"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc49601_the_offering"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE OFFERING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc49601_the_offering"><FONT SIZE=2><BR>
9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49601_risk_factors"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49601_risk_factors"><FONT SIZE=2><BR>
12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc49601_cautionary_note_regarding_forward-looking_statements"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc49601_cautionary_note_regarding_forward-looking_statements"><FONT SIZE=2><BR>
17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc49601_use_of_proceeds"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc49601_use_of_proceeds"><FONT SIZE=2><BR>
19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc49601_dividend_policy"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIVIDEND POLICY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc49601_dividend_policy"><FONT SIZE=2><BR>
20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de49601_dilution"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de49601_dilution"><FONT SIZE=2><BR>
21</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de49601_price_range_of_our_common_stock"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRICE RANGE OF OUR COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de49601_price_range_of_our_common_stock"><FONT SIZE=2><BR>
22</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49601_description_of_capital_stock"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49601_description_of_capital_stock"><FONT SIZE=2><BR>
23</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49601_description_of_securities_we_are_offering"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF SECURITIES WE ARE OFFERING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49601_description_of_securities_we_are_offering"><FONT SIZE=2><BR>
28</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49601_material_u.s._federal_tax_cons__mat04125"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF OUR COMMON
STOCK, PRE-FUNDED WARRANTS AND WARRANTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49601_material_u.s._federal_tax_cons__mat04125"><FONT SIZE=2><BR>
32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk49601_underwriting"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk49601_underwriting"><FONT SIZE=2><BR>
40</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk49601_legal_matters"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk49601_legal_matters"><FONT SIZE=2><BR>
47</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk49601_experts"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk49601_experts"><FONT SIZE=2><BR>
47</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk49601_where_you_can_find_more_information"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk49601_where_you_can_find_more_information"><FONT SIZE=2><BR>
47</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk49601_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk49601_incorporation_of_certain_documents_by_reference"><FONT SIZE=2><BR>
47</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1034152,FOLIO='i',FILE='DISK103:[18ZBT1.18ZBT49601]BG49601A.;19',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi49601_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi49601_about_this_prospectus"> </A>
<A NAME="toc_bi49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  ABOUT THIS PROSPECTUS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We have not, and the underwriters have not, authorized anyone to provide you with information that is different from that contained in this
prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. When you make a decision about whether to invest in our securities, you should not rely upon any
information other than the information contained in or incorporated by reference in this prospectus or in any free writing prospectus that we may authorize to be delivered or made available to you.
Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus or any free writing prospectus is correct after the date of this
prospectus or such free writing prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is
unlawful. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>For
investors outside the United States: we have not, and the underwriters have not, taken any action that would permit this offering or possession or distribution of this prospectus in any
jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the securities covered hereby and the distribution of this prospectus outside the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market
opportunity and market share, is based on information from our own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted by
third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be
reasonable. Our management estimates have not been verified by any independent source, and we have not independently verified any third-party information. In addition, assumptions and estimates of our
and our industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in "Risk Factors" beginning on
page&nbsp;12 of this prospectus and included under the section entitled "Risk Factors" in our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended March&nbsp;31, 2018, which is
incorporated by reference herein. These and other factors could cause our future performance to differ materially from our assumptions and estimates. See "Cautionary Note Regarding Forward-Looking
Statements." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to the registration statement of which this prospectus is a part were made
solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a
representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have proprietary rights to trademarks used in this prospectus, including MoveDMD&reg;. Solely for our convenience, trademarks and trade names referred to in this prospectus may appear
without the "&reg;" or "&#153;" symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent possible under applicable law, our
rights or the rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. Each trademark, trade name, or service mark of any other company appearing in this prospectus is the property of its respective holder. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=870565,FOLIO='1',FILE='DISK103:[18ZBT1.18ZBT49601]BI49601A.;9',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca49601_1_2"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca49601_prospectus_summary"> </A>
<A NAME="toc_ca49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  PROSPECTUS SUMMARY  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>This summary highlights information contained in other parts of this prospectus or incorporated by
reference into this prospectus from our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended
March&nbsp;31, 2018, our definitive proxy statement on Schedule&nbsp;14A filed with the Securities and Exchange Commission, or the SEC, on April&nbsp;26, 2018 and our other filings with the SEC
listed in the section of the prospectus entitled "Incorporation of Certain Documents by Reference." Because it is only a summary, it does not contain all of the information that you should consider
before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated by reference in
this prospectus. You should read the entire prospectus, the registration statement of which this prospectus is a part, and the information incorporated by reference herein in their entirety before
investing in our securities, including the "Risk Factors" section beginning on page&nbsp;12 of this prospectus and the information in our Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2017 and our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended March&nbsp;31, 2018, which include our financial statements and the related notes. Except as
otherwise indicated herein or as the context otherwise requires, references in this prospectus to "Catabasis," "the company," "we," "us" and "our" refer to Catabasis Pharmaceuticals,&nbsp;Inc. and
its consolidated subsidiary.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on our proprietary
Safely Metabolized And Rationally Targeted linker, or SMART Linker<SUP>SM</SUP>, drug discovery platform. Our SMART Linker drug discovery platform enables us to engineer product candidates that can
simultaneously modulate multiple targets in a disease. Our proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. We
have applied our SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, including our primary focus, edasalonexent, in development for the
treatment of Duchenne muscular dystrophy, or DMD. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
lead product candidate is edasalonexent, formerly known as CAT-1004, which we believe has the potential to be a disease-modifying therapy for all patients affected by DMD, regardless of the
underlying dystrophin mutation. Edasalonexent is an oral small molecule that inhibits NF-<FONT FACE="SYMBOL">k</FONT>B, or nuclear factor kappa-light-chain-enhancer of activated B cells.
DMD is an ultimately fatal genetic disorder involving
progressive muscle degeneration. The United States Food and Drug Administration, or FDA, has granted orphan drug, fast track and rare pediatric disease designations to edasalonexent for the treatment
of DMD. The European Commission, or EC, has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
MoveDMD&reg; Phase&nbsp;1/2 trial enrolled ambulatory boys four to seven years old with a genetically confirmed diagnosis of DMD who were steroid naive or had not used steroids for at
least six months prior to the trial. Boys enrolled in the trial were not limited to any specific dystrophin mutations and the 31 boys in the trial had 26 different dystrophin mutations. The MoveDMD
trial was designed to be conducted in three sequential parts, Phase&nbsp;1, Phase&nbsp;2, and an open-label extension, which is on-going. We have completed key efficacy and safety assessments from
the MoveDMD trial and have observed </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=689231,FOLIO='2',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_ca49601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>substantial
slowing of DMD disease progression as supported by functional assessments, magnetic resonance imaging, or MRI, results and biomarker results with edasalonexent treatment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
the open-label extension of the MoveDMD trial after more than a year of oral 100&nbsp;mg/kg/day edasalonexent treatment, we observed preserved muscle function and consistent improvements in all
four assessments of muscle function compared to the rates of change in the control period for boys prior to receiving edasalonexent treatment. Additionally, changes in non-effort based measures of
muscle health were seen, supporting the durability of edasalonexent treatment effects. Specifically, we observed statistically significant improvement in the rate of change in lower leg composite
magnetic resonance imaging T2 through 12, 24, 36 and 48&nbsp;weeks on oral 100&nbsp;mg/kg of edasalonexent treatment compared to the off-treatment control period. The relative proportion of fat in
muscle, which is referred to as fat fraction and is correlated with functional ability, can also be determined by magnetic resonance spectroscopy, or MRS. Improvements in the MRS fat fraction rate of
change through 48&nbsp;weeks of edasalonexent treatment compared to the off-treatment control period were observed in both soleus and vastus lateralis leg muscles, which are strongly correlated with
ambulatory function. Through more than one year of treatment, edasalonexent continued to be well tolerated with no safety signals observed in the trial. We plan to initiate a global Phase&nbsp;3
clinical trial for the treatment of DMD to evaluate the efficacy and safety of edasalonexent for registration purposes, dependent on raising capital. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>We
are also evaluating other diseases where the inhibition of NF-kB may be beneficial for further therapeutic applications of edasalonexent, such as Becker muscular dystrophy, or BMD. Patients with
BMD express low levels of dystrophin due to mutations in the dystrophin gene. Dystrophin production is reduced through the NF-kB-mediated induction of microRNAs that inhibit dystrophin translation.
Inhibition of NF-kB in BMD directly enhances dystrophin production. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
addition to edasalonexent, we have developed additional product candidates using our SMART Linker drug discovery platform as potential treatments for rare diseases, including CAT-5571, a potential
treatment for cystic fibrosis, or CF. CAT-5571 is a small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for
host defenses and is depressed in CF. We have completed investigational new drug, or IND, application-enabling activities for CAT-5571. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As
of April&nbsp;30, 2018, we owned six issued U.S. patents with composition of matter and method of use claims directed to edasalonexent and four issued U.S. patents with composition of matter and
method of use claims directed to CAT-5571. These patents are expected to expire between 2029 and 2031, without taking into account potential patent term extensions. In addition, our patent portfolio
includes over 100 issued foreign patents, over 10 pending U.S. patent applications and over 35 pending foreign patent applications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>For
additional information regarding our business, see the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and
the related notes thereto included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017 and our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended
March&nbsp;31, 2018, as well as the section entitled "Business" included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, each of which is incorporated by
reference into this prospectus. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=904340,FOLIO='3',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_ca49601_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Product Candidates  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The following chart summarizes key information regarding our product candidates. We hold rights to all of our product candidates throughout the world. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g525311.jpg" ALT="GRAPHIC" WIDTH="607" HEIGHT="318">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Edasalonexent  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Edasalonexent is a SMART Linker conjugate of salicylic acid and the omega-3 fatty acid docosahexaenoic acid, or DHA, a naturally occurring unsaturated fatty
acid with anti-inflammatory properties. We designed edasalonexent to inhibit NF-<FONT FACE="SYMBOL">k</FONT>B, a protein that is activated in DMD and that drives inflammation, fibrosis and
muscle degeneration, and suppresses muscle regeneration. We have reported results from Phase&nbsp;1, Phase&nbsp;2 and the open-label extension of the MoveDMD trial through administration of
edasalonexent for up to 60&nbsp;weeks, as described further below under "&nbsp;&#150;&nbsp;Edasalonexent Clinical Development". The FDA has granted edasalonexent orphan drug, fast track
and rare pediatric disease designations for the treatment of DMD. The EC has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Edasalonexent Clinical Development  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MoveDMD Phase&nbsp;1/2 Trial of Edasalonexent in Patients with DMD  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our MoveDMD Phase&nbsp;1/2 trial enrolled ambulatory boys ages four to seven with a genetically confirmed diagnosis of DMD, regardless of mutation, who were
steroid naive or had not used steroids for at least six months prior to the trial. The MoveDMD trial was designed to be conducted in three sequential parts, Phase&nbsp;1, Phase&nbsp;2, and an
open-label extension, which is on-going. We have completed key efficacy and safety assessments from the MoveDMD trial and have observed substantial slowing of DMD disease progression as supported by
functional assessments, MRI results and biomarker results with edasalonexent treatment. Edasalonexent has been well tolerated with no clinical safety signals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have evaluated the data collected in the MoveDMD trial against two benchmarks. Our MoveDMD trial design pre-specified an assessment of the rate of change of muscle function and magnetic resonance,
or MR, for boys participating in the MoveDMD trial during off-treatment periods prior to the Phase&nbsp;2 portion of the trial, which averaged more than 6&nbsp;months. We also compared the </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=493772,FOLIO='4',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_ca49601_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>MoveDMD
trial data to an ImagingDMD natural history study in which muscle function and MR were assessed annually. We observed a decline in muscle function in boys in the MoveDMD trial during the
off-treatment control period consistent with the ImagingDMD natural history study observations of muscle function for boys not receiving corticosteroids in this age range. We believe the ImagingDMD
data provide important corroboration of the MoveDMD off-treatment control period observations of muscle function. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Changes
in MRI measures, particularly the relative proportion of fat in muscle, which is referred to as fat fraction, have been correlated in natural history studies with longer-term changes in
clinically meaningful measures of functional activity. Histological changes in muscle in DMD include inflammation present from an early age, and, as boys with DMD get older, the amount of fat in their
muscles increases with consequent loss of functional abilities. While MRI T2 measures both
inflammation and fat, MRI T2 increases over time in DMD largely reflect fat infiltration and are strongly correlated with worse performance on timed function tests and predict future loss of
functional abilities. MRS measures fat fraction and is strongly correlated with MRI T2, and is similarly correlated with worse performance on timed function tests and predict future loss of functional
abilities. We observed an increase in MRI T2 and an increase in MRS fat fraction in boys in the MoveDMD trial during the off-treatment control period. In addition, in the ImagingDMD natural history
study, where more than three quarters of the boys with MR measurements were receiving corticosteroids, the MRI&nbsp;T2 and MRS fat fraction increased year after year. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>In
April 2018, we reported data showing significantly slowed DMD disease progression as measured by MR through 48&nbsp;weeks of treatment. We reported statistically significant improvement in the
rate of change in lower leg composite MRI T2 through 12, 24, 36 and 48&nbsp;weeks on oral 100&nbsp;mg/kg of edasalonexent treatment compared to the off-treatment control period
(p&#60;0.05 for all time points<SUP>2</SUP>). The rate of increase in MRS fat fraction in the soleus and vastus lateralis muscles with edasalonexent treatment in the MoveDMD trial were
numerically less through 48&nbsp;weeks compared to the rate of increase in boys prior to treatment. MRI T2 and MRS fat fraction rates of change in boys in the MoveDMD trial were less than those
observed in the ImagingDMD natural history study. In recent guidance on DMD development, the FDA stated that it considers MRI measures to be important supportive early endpoints demonstrating
therapeutic effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Consistent
with the edasalonexent MR data, in February 2018, we reported a preservation of muscle function and slowing of DMD disease progression in the Phase&nbsp;2 MoveDMD trial and open-label
extension in boys treated with edasalonexent compared to the rates of change during the control period prior to receiving edasalonexent. Through a year of treatment, the 100&nbsp;mg/kg/day treatment
group showed consistent and clinically meaningful improvements in rates of decline compared to rates of change during the control period across all four assessments of muscle function in the trial:
the three timed function tests (10-meter walk/run, 4-stair climb and time to stand), as well as the North Star Ambulatory Assessment, an integrated global assessment of muscle function. In recent
guidance on DMD development, the FDA identified these four assessments of muscle function as age-appropriate tests for assessing DMD disease progression in young boys. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Additional
supportive measures of muscle health also reinforce the positive edasalonexent treatment effects observed in the 100&nbsp;mg/kg/day treatment group. All four muscle enzymes tested
(creatine kinase, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase) were significantly decreased compared to baseline following edasalonexent treatment at 12&nbsp;weeks
and later time points through 60&nbsp;weeks (p&#60;0.05), consistent with the observations that edasalonexent slowed muscle degeneration and improve muscle integrity. Biomarker results
showed that C-reactive protein, or CRP, </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1><SUP>1</SUP></FONT></DT><DD style="font-family:times;"><FONT SIZE=1>P-value
is a conventional statistical method for measuring the statistical significance of clinical results. A p-value of 0.05 or less represents
statistical significance, meaning that there is a 1-in-20 or less statistical probability that the observed results occurred by chance.</FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1024709,FOLIO='5',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_ca49601_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>was
significantly decreased with edasalonexent at 12, 24, 36 and 48&nbsp;weeks compared to baseline in the 100&nbsp;mg/kg/day treatment group (p&#60;0.001). CRP is a well-characterized
blood test marker that provides a global assessment of inflammation and is elevated in boys affected by DMD. The significant decrease observed in CRP supports a conclusion that the biological activity
of edasalonexent in inhibiting NF-kB can decrease inflammation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
addition, to provide a preclinical understanding of a potential future clinical dosing regimen, we developed a population pharmacokinetic model using data from multiple clinical trials. We observed
in
the MoveDMD Phase&nbsp;1 data that edasalonexent produces dose-related reductions in NF-<FONT FACE="SYMBOL">k</FONT>B regulated and inflammation-related gene transcripts that are driven
by C<SUB>trough</SUB>, which is the lowest concentration of drug substance prior to receiving the next dose. In preclinical models, we observed that C<SUB>trough</SUB> is a driver of efficacy. Our
pharmacokinetic/pharmacodynamic profiles and population pharmacokinetic modeling suggest that dosing frequency to maximize time over a certain threshold drug concentration, rather than maximum
concentration or drug total exposure, primarily drives pharmacologic effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Edasalonexent
has been well tolerated in the MoveDMD trial with no clinical safety signals observed to date. The majority of adverse events, or AEs, have been mild in nature with no serious AEs, no
drug discontinuations and no dose reductions. Height, weight and BMI growth patterns were similar to standard growth curves for unaffected boys in the age range of the boys participating in the
MoveDMD trial, unlike the adverse treatment effects on these growth patterns with the current standard of care in DMD, corticosteroids. Additionally, boys with DMD in this age range typically have
resting tachycardia, a heart rate that exceeds the normal resting rate, and the heart rate of the boys treated with edasalonexent decreased toward age-normative values during treatment through the
last measurements taken at 48&nbsp;weeks. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Planned Phase&nbsp;3 Clinical Trial  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We plan to initiate a single global Phase&nbsp;3 clinical trial for the treatment of DMD in 2018 with top-line results expected in the second quarter of
2020, assuming the completion of this offering. The purpose of the trial is to evaluate the efficacy and safety of edasalonexent for registration purposes. The design of this randomized, double-blind,
placebo-controlled trial has been informed by discussions with the FDA and the European Medicines Agency. We expect that the Phase&nbsp;3 clinical trial will have many key elements in common with
the Phase&nbsp;2 trial, including the patient population and endpoints. We anticipate enrolling approximately 125 boys, four to seven years old, who have not been on steroids for at least
6&nbsp;months. We may consider enrolling boys on a stable dose of EXONDYS 51, one of two therapies approved by the FDA for the treatment of DMD, dependent on final trial design. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview of DMD  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>DMD is a rare pediatric disorder involving progressive muscle degeneration that eventually leads to death. DMD is caused by various mutations in the
dystrophin gene that result in a lack of functional dystrophin in muscle fibers, which renders muscle fibers more susceptible to mechanical stress. Dystrophin is a protein that resides in the membrane
of muscle cells and is critical to the structural and membrane stability of muscle fibers in skeletal, diaphragm, and cardiac muscle. When muscles contract or stretch during normal use, the absence of
normally functioning dystrophin
results in activation of the NF-<FONT FACE="SYMBOL">k</FONT>B pathway, triggering inflammation in the muscles, initiating muscle degeneration, and reducing the ability of muscles to
regenerate. As muscle damage progresses, connective and adipose tissues replace muscle fibers, resulting in inexorable muscle weakness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>DMD
is the most common fatal genetic childhood disease and it occurs almost exclusively in males, occurring in approximately 1 in 3,500 live male births. Based on this incidence rate, we estimate that </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=942462,FOLIO='6',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_ca49601_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>DMD
affects a total of approximately 15,000 patients in the United States and approximately 19,000 patients in the European Union. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Children
with DMD typically begin to show symptoms of disease between ages two and five, when they develop a waddling gait, frequently fall and have difficulty rising from the floor. Progressive
weakness then develops in the muscles in the arms, legs and trunk. This muscle weakness is accompanied by fixations, or contractures, of joints, such as knees, hips and elbows. By age eight, most
patients have difficulty ascending stairs. Patients typically lose walking ability between the ages of ten and fourteen and, by about twelve years of age, most people with DMD are unable to walk and
need to use a wheelchair on a regular basis. Patients' cardiac and respiratory muscles are also adversely affected, typically requiring use of ventilators in their late teens. Progressive weakening of
cardiac and respiratory muscles of DMD patients eventually results in death, generally in the patient's mid-twenties. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-5571  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>CAT-5571 is a SMART Linker conjugate that contains cysteamine, a naturally occurring molecule that is a degradation product of the amino acid cysteine, and
DHA. We have developed CAT-5571 as a potential oral treatment for CF, designed to activate autophagy and thereby restore host defense. Autophagy is a mechanism for recycling cellular components and
digesting
pathogens, which is depressed in CF. CAT-5571 has been shown to restore autophagy, reestablish host defense and enhance the clearance of pathogens, including </FONT><FONT SIZE=2><I>P.
aeruginosa</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>B. cenocepacia</I></FONT><FONT SIZE=2> in preclinical models of CF. We have completed IND-enabling activities for CAT-5571. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>CF
is a rare, chronic, genetic, life-shortening orphan disease that affects over 70,000 patients worldwide, predominantly in the Caucasian population. In CF, a malfunctioning cystic fibrosis
transmembrane conductance regulator ion channel impairs chloride secretion, with deleterious effects on multiple organs, and particularly devastating effects on pulmonary, intestinal and pancreatic
function. Patients affected with CF are also predisposed to respiratory failure caused by persistent lung infections, notably bacteria and most commonly </FONT><FONT SIZE=2><I>P.
aeruginosa,</I></FONT><FONT SIZE=2> that are difficult to treat with standard antibiotics. CF patients have frequent pulmonary exacerbations due to their inability to clear the persistent lung
infections. Advancement in research and treatments have extended the life expectancy for those living with CF, however, there is currently no cure. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We were incorporated under the laws of the State of Delaware on June&nbsp;26, 2008 under the name Catabasis Pharmaceuticals,&nbsp;Inc. Our executive
offices are located at One Kendall Square, Bldg. 1400E, Suite B14202, Cambridge, Massachusetts 02139, and our telephone number is (617)&nbsp;349-1971. Our website address is www.catabasis.com. The
information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual
reference. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We qualify as an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may remain an emerging
growth company until the end of our 2020 fiscal year. However, if certain events occur prior to the end of such period, including if we become a "large accelerated filer," our annual gross revenue
exceeds $1.07&nbsp;billion, or we issue more than $1.0&nbsp;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such
period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=355193,FOLIO='7',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_ca49601_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P style="font-family:times;"><FONT SIZE=2>applicable
to other public companies that are not emerging growth companies. These exemptions include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced disclosure about our executive compensation arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> exemption from holding non-binding advisory votes on executive compensation, including golden parachute arrangements; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Accordingly,
the information contained in this prospectus, and the information incorporated herein by reference, may be different than the information you receive from other public companies in which
you hold stock. However, we have irrevocably elected not to avail ourselves of the extended transition period for complying with new or revised accounting standards, and, therefore, we are subject to
the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=669894,FOLIO='8',FILE='DISK103:[18ZBT1.18ZBT49601]CA49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc49601_1_9"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc49601_the_offering"> </A>
<A NAME="toc_cc49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common Units offered</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>We are offering $30,000,000 of Common Units. Each Common Unit will consist of one share of our common stock and a warrant to purchase one share of our common stock at an exercise price per whole share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(each a "Warrant").</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pre-funded Units offered</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We are also offering to those purchasers, if any, whose purchase of Common Units in this offering would otherwise result in
the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the
opportunity to purchase, if the purchaser so chooses, pre-funded units (each a "Pre-funded Unit") in lieu of Common Units that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or, at the election of the purchaser,
9.99%) of our outstanding common stock. Each Pre-funded Unit will consist of a pre-funded warrant to purchase one share of our common stock at an exercise price of $0.01 per share (each a "Pre-funded Warrant") and a Warrant. The purchase price of
each Pre-funded Unit is equal to the price per Common Unit being sold to the public in this offering, minus $0.01. The Pre-funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-funded Warrants are
exercised in full. For each Pre-funded Unit we sell, the number of Common Units we are offering will be decreased on a one-for-one basis. Because we will issue one Warrant as part of each Common Unit or Pre-funded Unit, the number of Warrants sold in
this offering will not change as a result of a change in the mix of the Common Units and Pre-funded Units sold. This prospectus also relates to the offering of the shares of our common stock issuable upon exercise of the Pre-funded
Warrants.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=12,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=902553,FOLIO='9',FILE='DISK103:[18ZBT1.18ZBT49601]CC49601A.;16',USER='HYUNG',CD=';4-JUN-2018;10:32' -->
<A NAME="page_cc49601_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants offered</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each Warrant included in the Common Units and the Pre-funded will have an exercise price per whole share of common stock of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, will be immediately exercisable and will be exercisable for five years from the date of issuance. This prospectus also relates to the offering of the shares of our common stock issuable
upon exercise of the Warrants.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding immediately following this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares assuming we sell the Common Units (and no
Pre-funded Units) being offered in this offering at an assumed public offering price per unit of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which was the reported closing price of our common stock on the Nasdaq Global
Market on June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, and assuming no exercise of the Warrants being offered in this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no sale of any Pre-funded Units, after deducting the underwriting discount and commissions and estimated offering expenses payable by us. These estimates
exclude the proceeds, if any, from exercise of the Warrants sold in this offering. We plan to use the net proceeds from this offering to fund our planned Phase&nbsp;3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy,
as well as for working capital and general corporate purposes. Based on our planned use of the net proceeds from this offering and our existing cash and cash equivalents, we estimate that such funds will be sufficient to enable us to obtain top-line
data from our planned Phase&nbsp;3 clinical trial of edasalonexent, and fund our operating expenses, debt service and capital expenditure requirements at least into the second quarter of 2020. See the "Use of Proceeds" section in this prospectus for
a more complete description of the intended use of proceeds from this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus beginning on page&nbsp;12 hereof and the "Risk Factors"
section included in our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended March&nbsp;31, 2018, which is incorporated by reference, for a discussion of factors to consider carefully before deciding to invest in our
securities.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=13,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=228591,FOLIO='10',FILE='DISK103:[18ZBT1.18ZBT49601]CC49601A.;16',USER='HYUNG',CD=';4-JUN-2018;10:32' -->
<A NAME="page_cc49601_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Market symbol</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Our common stock is listed on the Nasdaq Global Market under the symbol "CATB". There is no established public trading market for the
Warrants or the Pre-funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Warrants or the Pre-funded Warrants on any securities exchange or other nationally recognized trading system. Without an
active trading market, the liquidity of the Warrants or the Pre-funded Warrants will be limited.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 29,035,502 shares of our common stock outstanding as of April&nbsp;30, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 3,660,952 shares of our common stock issuable upon the exercise of stock options outstanding as of April&nbsp;30, 2018 at a weighted-average
exercise price of $3.76 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 954,642 shares of our common stock available for future issuance as of April&nbsp;30, 2018 under our 2015 stock incentive plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 24,566 shares of our common stock issuable upon the exercise of warrants outstanding as of April&nbsp;30, 2018, at an exercise price of
$12.2114 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 760,111 shares of our common stock available for future issuance as of April&nbsp;30, 2018 under our 2015 employee stock purchase plan. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, all information in this prospectus assumes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no exercise of the outstanding options or warrants described in the bullets above; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no sale of Pre-funded Units in this offering and no exercise of the Warrants being offered in this offering. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=14,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=35245,FOLIO='11',FILE='DISK103:[18ZBT1.18ZBT49601]CC49601A.;16',USER='HYUNG',CD=';4-JUN-2018;10:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da49601_1_12"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49601_risk_factors"> </A>
<A NAME="toc_da49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  RISK FACTORS  <BR>  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>Investing in our securities involves a high degree of risk. Before you decide to invest in our
securities, you should consider carefully the risks described below and the risks discussed under the section entitled "Risk Factors" in our Quarterly Report on Form&nbsp;10-Q for the quarterly
period ended March&nbsp;31, 2018, which is incorporated by reference herein, together with the other information contained in this prospectus and the information incorporated by reference herein and
in any free writing prospectus that we may authorize for use in connection with this offering. We believe the risks described below and incorporated by reference herein are the risks that are material
to us as of the date of this prospectus. If any of these risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely
affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment.</I></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to Our Financial Position and Need for Additional Capital  </I></B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if this offering is successful, we will need substantial additional funding. If we are unable to raise
capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process
that takes years to complete. We expect our expenses to increase, if and to the extent of certain ongoing activities, particularly if we initiate new clinical trials of our product candidates, such as
our planned Phase&nbsp;3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy, or DMD, or initiate new research and preclinical development efforts for and seek marketing
approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we may incur significant commercialization expenses related to product sales,
marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a future collaborator. Furthermore, we have incurred
and will continue to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our
continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development programs or any future
commercialization efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
will be required to expend significant funds in order to advance the development of edasalonexent. Even if this offering is successful, we will not have sufficient funding to complete clinical
development or commercialization of edasalonexent. Accordingly, we will need to raise additional funding and such funding may not be available to us on acceptable terms, on a timely basis or at all.
In the event that we are unable to obtain such funding on acceptable terms and in a timely manner or at all, we may not be able to complete the clinical development or commercialization of
edasalonexent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Further,
our ability to obtain additional debt financing may be limited by covenants we have made under our loan and security agreement, with MidCap Financial Trust, or MidCap, Flexpoint MCLS
SPV&nbsp;LLC, or Flexpoint, and Square 1 Bank, or Square 1, including our negative pledge with respect to intellectual property in favor of Flexpoint and Square 1, as well as our pledge to MidCap,
Flexpoint and Square 1 of substantially all of our assets, other than our intellectual property, as collateral. Our failure to raise capital on acceptable terms as and when needed would have a
material adverse effect on our business, results of operations, financial condition and ability to pursue our business strategy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=642740,FOLIO='12',FILE='DISK103:[18ZBT1.18ZBT49601]DA49601A.;13',USER='HYUNG',CD=';4-JUN-2018;10:40' -->
<A NAME="page_da49601_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
believe that the anticipated net proceeds from this offering, together with our existing cash, will enable us to obtain top-line data from our planned Phase&nbsp;3 clinical trial of edasalonexent
for the treatment of DMD and fund operations into the second quarter of 2020. Without giving effect to the anticipated net proceeds from this offering, we expect that our existing cash will be
sufficient to fund operations through December 2018. Based on our available cash resources, we do not have sufficient cash on hand to support current operations for at least the next twelve months
from the date of filing our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended March&nbsp;31, 2018. This condition raises substantial doubt about our ability to continue as a going
concern. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
estimate as to how long we expect our cash and cash equivalents to be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital
resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently
anticipate, and we may need to seek additional funds sooner than planned. Changes in estimates and assumptions underlying our operating plan could impact our ability to continue as a going concern for
a period of one year from the date of issuance of the financial statements contained in the registration statement of which this prospectus is a part. We believe that the impact of these changes would
be mitigated by our ability to significantly delay or reduce certain direct program expenditures. Our future funding requirements, both short-term and long-term, will depend on many factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, our product candidates and
potential product candidates, including current and future clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to enter into and the terms and timing of any additional collaborations, licensing or other arrangements that we may establish; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and characteristics of future product candidates that we pursue and their development requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the outcome, timing and costs of seeking regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not
the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to receipt of marketing approval, revenue, if any, received from commercial sales of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending
against intellectual property related claims; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of operating as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our independent registered public accounting firm has included an explanatory paragraph relating to our
ability to continue as a going concern in its report on our audited financial statements included in this prospectus.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The report from our independent registered public accounting firm for the year ended December&nbsp;31, 2017 includes an explanatory paragraph stating that
our recurring losses from operations since inception and required additional funding to finance our operations raise substantial doubt about our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=397297,FOLIO='13',FILE='DISK103:[18ZBT1.18ZBT49601]DA49601A.;13',USER='HYUNG',CD=';4-JUN-2018;10:40' -->
<A NAME="page_da49601_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ability
to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected,
and we may be unable to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are
carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. After this offering, future reports from our independent registered public
accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future
and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially
reasonable terms or at all. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Risks Related to this Offering  </I></B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase securities in this offering, you will suffer immediate dilution of your investment.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The public offering prices of the Common Units and the Pre-funded Units are substantially higher than the net tangible book value per share of our common
stock. Therefore, if you purchase securities in this offering, you will pay an effective price per share of common stock you acquire that substantially exceeds our net tangible book value per share
after this offering. Based on an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Common Unit, which was the last reported sale price of our common stock on the Nasdaq Global Market on
June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, and assuming no sale of any Pre-funded Units in this offering, no exercise of the Warrants being offered in this offering, that no value is attributed to such
Warrants and that such Warrants are classified as and accounted for as equity, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between our as
adjusted
net tangible book value per share after giving effect to this offering and the assumed public offering price of the Common Units. In addition, if previously issued options to acquire common stock are
exercised at prices below the offering price or the Warrants are accounted for as liabilities, you will
experience further dilution. For a further description of the dilution that you will experience immediately after this offering, see "Dilution." </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There is no public market for the Pre-Funded Warrants or the Warrants to purchase shares of our common stock
being offered by us in this offering.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>There is no established public trading market for the Pre-Funded Warrants or the Warrants being offered in this offering, and we do not expect a market to
develop. In addition, we do not intend to apply to list the Pre-Funded Warrants or the Warrants on any national securities exchange or other nationally recognized trading system, including the Nasdaq
Global Market. Without an active market, the liquidity of the Pre-Funded Warrants and the Warrants will be limited. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may experience future dilution as a result of future equity offerings.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock at prices that may not be the same as the public offering prices of the Common Units and the Pre-funded Units in this offering. We may sell shares or other securities in any other
offering at prices that are less than the prices paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
stockholders. The prices per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower
than the prices paid by investors in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=273036,FOLIO='14',FILE='DISK103:[18ZBT1.18ZBT49601]DA49601A.;13',USER='HYUNG',CD=';4-JUN-2018;10:40' -->
<A NAME="page_da49601_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion over the use of our cash and cash equivalents, including the net proceeds we receive
in this offering, and may not use them effectively.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our management has broad discretion to use our cash and cash equivalents, including the net proceeds we receive in this offering, to fund our operations and
could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock.
The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to
decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses
value. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Holders of Pre-funded Warrants and Warrants purchased in this offering will have no rights as common
stockholders until such holders exercise their Pre-funded Warrants or Warrants and acquire our common stock.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Until holders of Pre-funded Warrants or Warrants acquire shares of our common stock upon exercise thereof, such holders will have no rights with respect to
the shares of our common stock underlying the Pre-funded Warrants and the Warrants. Upon exercise of the Pre-funded Warrants or Warrants, the holders will be entitled to exercise the rights of a
common stockholder only as to matters for which the record date occurs after the exercise date. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The Warrants are speculative in nature.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The Warrants do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely
represent the right to acquire shares of common stock at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the Warrants may exercise their right
to acquire the common stock and pay an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, subject to certain adjustments, prior to five years from the date of issuance, after which
date any
unexercised Warrants will expire and have no further value. Moreover, following this offering, the market value of the Warrants, if any, is uncertain and there can be no assurance that the market
value of the Warrants will equal or exceed their imputed offering price. The Warrants will not be listed or quoted for trading on any market or exchange. There can be no assurance that the market
price of the common stock will ever equal or exceed the exercise price of the Warrants, and consequently, it may not ever be profitable for holders of the Warrants to exercise the Warrants. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We might not be able to utilize a significant portion of our net operating loss carryforwards and tax credit
carryforwards.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As of December&nbsp;31, 2017, we had approximately $152.1&nbsp;million of federal and $150.4&nbsp;million of state net operating loss carryforwards to
offset future taxable income, if any. Such net operating loss carryforwards expire at varying times through the year 2037, if not utilized. We had
approximately $4.5&nbsp;million of federal and $1.8&nbsp;million of state tax credit carryforwards available to reduce future tax liabilities as of December&nbsp;31, 2017, which will expire at
varying times through the year 2037. The Internal Revenue Code of 1986, as amended, or the Code, provides for a limitation on the annual use of net operating losses and other tax attributes (such as
research and development tax credit carryforwards) in certain circumstances. Under Section&nbsp;382 of the Code and corresponding provisions of state law, if a corporation undergoes an "ownership
change," which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation's ability to use its pre-change net operating loss
carryforwards and other pre-change tax attributes to offset its </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=453498,FOLIO='15',FILE='DISK103:[18ZBT1.18ZBT49601]DA49601A.;13',USER='HYUNG',CD=';4-JUN-2018;10:40' -->
<A NAME="page_da49601_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>post-change
income may be limited. At this time, we have not completed a study to assess whether an ownership change under Section&nbsp;382 of the Code has occurred, or whether there have been
multiple ownership changes since our formation, due to the costs and complexities associated with such a study. We may have experienced various ownership changes, as defined by the Code, as a result
of past financing transactions, and we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, including this offering, some of which may be outside of
our control. Accordingly, our ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against
future taxes. Therefore, we may not be able to take full advantage of these carryforwards for federal or state income tax purposes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=622992,FOLIO='16',FILE='DISK103:[18ZBT1.18ZBT49601]DA49601A.;13',USER='HYUNG',CD=';4-JUN-2018;10:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc49601_1_17"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49601_cautionary_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dc49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This prospectus and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and
uncertainties. All statements, other than statements of historical facts, contained in this prospectus and the documents incorporated by reference herein, including statements regarding our strategy,
future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words
"anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>These
forward-looking statements include, among other things, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to initiate a single global Phase&nbsp;3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy, report
top-line data from the Phase&nbsp;3 clinical trial in the second quarter of 2020, and continue to evaluate data from the open-label extension of our MoveDMD&reg; clinical trial of
edasalonexent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to identify, develop and commercialize novel therapeutics based on our SMART Linker<SUP>SM</SUP> drug discovery platform; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ongoing and planned clinical trials for edasalonexent, whether conducted by us or by any future collaborators, including the timing of
initiation of these trials and of the anticipated results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to enter into collaborations for the development and commercialization of product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential benefits of any future collaboration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to receive research and development funding and achieve anticipated milestones under any future collaborations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our commercialization, marketing and manufacturing capabilities and strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our intellectual property position and strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to identify additional products or product candidates with significant commercial potential; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations related to the use of proceeds from this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to continue as a going concern; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments relating to our competitors and our industry; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of government laws and regulations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=20,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=335889,FOLIO='17',FILE='DISK103:[18ZBT1.18ZBT49601]DC49601A.;23',USER='HYUNG',CD=';4-JUN-2018;10:38' -->
<A NAME="page_dc49601_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>or
events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements
included in this prospectus, particularly in the "Risk Factors" section of this prospectus and in the "Risk Factors" section of our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended
March&nbsp;31, 2018, which is incorporated herein by reference, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>You
should read this prospectus, the information incorporated by reference herein and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part
completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether
as a result of new information, future events or otherwise, except as required by law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=21,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=934132,FOLIO='18',FILE='DISK103:[18ZBT1.18ZBT49601]DC49601A.;23',USER='HYUNG',CD=';4-JUN-2018;10:38' -->
<A NAME="page_dc49601_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49601_use_of_proceeds"> </A>
<A NAME="toc_dc49601_2"> </A>
<BR></FONT><FONT SIZE=3><B>  USE OF PROCEEDS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no sale of any Pre-funded
Units, after deducting the underwriting discount and commissions and estimated offering expenses payable by us. The public offering price per Common Unit or Pre-funded Unit will be determined between
us, the underwriters and investors based on market conditions at the time of pricing and may be at a discount to the current market price of our common stock. These estimates exclude the proceeds, if
any, from exercise of the Warrants sold in this offering. If all of the Warrants sold in this offering were to be exercised in cash at an assumed exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of
common
stock, which was the reported closing price of our common stock on the Nasdaq Global Market on June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, we would receive additional net proceeds of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We cannot predict when or if these Warrants will be exercised. It is possible that these Warrants may expire and may never be exercised. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
plan to use the net proceeds from this offering to fund our planned Phase&nbsp;3 clinical trial of edasalonexent for the treatment of Duchenne muscular dystrophy, as well as for working capital
and general corporate purposes. Without additional funding beyond this offering, we do not intend to continue research and development activities for our other pipeline programs. We cannot predict
with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. Accordingly, our management will have broad discretion and flexibility in applying
the net proceeds from the sale of securities sold pursuant to this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Based
on our planned use of the net proceeds from this offering and our existing cash and cash equivalents, we estimate that such funds will be sufficient to enable us to obtain top-line data from our
planned Phase&nbsp;3 clinical trial of edasalonexent, and fund our operating expenses, debt service and capital expenditure requirements at least into the second quarter of 2020. We have based this
estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not expect that the net proceeds from this offering and our
existing cash and cash equivalents will be sufficient to enable us to fund the completion of development of edasalonexent or any of our other product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in short term, investment grade, interest-bearing instruments and U.S. government securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=22,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=844192,FOLIO='19',FILE='DISK103:[18ZBT1.18ZBT49601]DC49601A.;23',USER='HYUNG',CD=';4-JUN-2018;10:38' -->
<A NAME="page_dc49601_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49601_dividend_policy"> </A>
<A NAME="toc_dc49601_3"> </A>
<BR></FONT><FONT SIZE=3><B>  DIVIDEND POLICY  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. In addition, our ability to pay cash dividends on
our common stock is prohibited by the covenants of our credit facility with MidCap Financial Trust, Flexpoint MCLS SPV&nbsp;LLC and Square 1 Bank. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=23,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=476319,FOLIO='20',FILE='DISK103:[18ZBT1.18ZBT49601]DC49601A.;23',USER='HYUNG',CD=';4-JUN-2018;10:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de49601_1_21"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49601_dilution"> </A>
<A NAME="toc_de49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  DILUTION  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our net tangible book value as of March&nbsp;31, 2018 was $12.9&nbsp;million, or $0.45 per share of common stock. Net tangible book value
per share is equal to our total tangible assets, less our total liabilities, divided by the number of shares outstanding as of the date in question. Dilution with respect to net tangible book value
per share represents the difference between the effective price per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock
immediately after this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>After
giving effect to the assumed issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Units in this offering at an assumed public offering price per Common Unit of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which was the reported
closing price of our common stock on the Nasdaq Global Market on June&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, after deducting the estimated underwriting discount and commissions and estimated offering expenses
payable by us, and assuming no sale of any Pre-funded Units in this offering, no exercise of the Warrants offered hereby, that no value is attributed to such
Warrants and that such Warrants are classified as and accounted for as equity, our as adjusted net tangible book value as of March&nbsp;31, 2018 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. This represents an immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate
dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors purchasing our common stock in this offering. The following table illustrates this calculation on a per share basis: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed public offering price per Common Unit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net tangible book value per share as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to the offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As adjusted net tangible book value per share as of March&nbsp;31, 2018, after giving effect to the offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors purchasing our common stock in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>In
addition, if previously issued options to acquire common stock are exercised at prices below the public offering price or the Warrants are accounted for as liabilities, you will experience further
dilution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>A
$0.10 increase or decrease in the assumed public offering price per Common Unit of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;would increase or decrease our as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dilution per share to investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting the estimated underwriting discount and commissions and
estimated offering
expenses payable by us, and assuming no sa le of any Pre-funded Units in this offering and no exercise of the Warrants being offered in this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
table and discussion above are based on 29,035,502 shares of our common stock outstanding as of March&nbsp;31, 2018. The number of shares outstanding as of March&nbsp;31, 2018
excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 3,775,626 shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2018, at a weighted-average
exercise price of $3.73 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 839,975 shares of our common stock available for future issuance as of March&nbsp;31, 2018 under our 2015 stock incentive plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 24,566 shares of our common stock issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2018, at an exercise price of
$12.2114 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 760,111 shares of our common stock available for future issuance as of March&nbsp;31, 2018 under our 2015 employee stock purchase plan. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=350542,FOLIO='21',FILE='DISK103:[18ZBT1.18ZBT49601]DE49601A.;23',USER='HYUNG',CD=';4-JUN-2018;11:01' -->
<A NAME="page_de49601_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49601_price_range_of_our_common_stock"> </A>
<A NAME="toc_de49601_2"> </A>
<BR></FONT><FONT SIZE=3><B>  PRICE RANGE OF OUR COMMON STOCK  <BR>  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our common stock has been publicly traded on the Nasdaq Global Market under the symbol "CATB" since June&nbsp;25, 2015. Prior to that time, there was no
public market for our common stock. As of May&nbsp;31, 2018, there were approximately&nbsp;32 stockholders of record of our common stock, and the closing price of our common stock reported on the
Nasdaq Global Market on such date was $1.74 per share. The following table sets forth the high and low intraday sales prices of our common stock as reported on the Nasdaq Global Market for the periods
indicated: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2018</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter (through May&nbsp;31, 2018)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2017</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.08</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.09</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2016</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2015</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>NA</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter (from June&nbsp;25, 2015)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=25,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=670460,FOLIO='22',FILE='DISK103:[18ZBT1.18ZBT49601]DE49601A.;23',USER='HYUNG',CD=';4-JUN-2018;11:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg49601_1_23"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49601_description_of_capital_stock"> </A>
<A NAME="toc_dg49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  DESCRIPTION OF CAPITAL STOCK  <BR>  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This
description is based upon, and is qualified by reference to, our certificate of incorporation, our by-laws and applicable provisions of Delaware corporate law. You should read our certificate of
incorporation and by-laws, which are filed
as exhibits to the registration statement of which this prospectus forms&nbsp;a part, for the provisions that are important to you. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Our
authorized capital stock consists of 150,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. As of April&nbsp;30,
2018, 29,035,502 shares of common stock were outstanding and no shares of preferred stock were outstanding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Voting Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, except that unless
otherwise required by law, holders of our common stock are not entitled to vote on any amendment to the certificate of incorporation that relates solely to the terms of one or more outstanding series
of preferred stock, if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such other series, to vote thereon pursuant to the
certificate of incorporation. Holders of our common stock do not have cumulative voting rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>An
election of directors will be decided by a plurality of the votes cast by the stockholders entitled to vote on the election at a duly held stockholders' meeting at which a quorum is present. All
other questions will be decided by a majority of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present, except when a different
vote is required by law, our certificate of incorporation or by-laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential
dividend or other rights of any series of preferred stock that we may designate and issue in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Liquidation and Dissolution.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets
available for distribution to stockholders after the
payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Other Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of
common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> Transfer Agent and Registrar.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> Listing on The Nasdaq Global Market.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Global Market under the symbol "CATB." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=26,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=362053,FOLIO='23',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We currently have no outstanding shares of preferred stock. Under our restated certificate of incorporation, we are authorized to issue "blank check"
preferred stock, which may be issued in one or more series upon authorization of our board of directors. Our board of directors is authorized to fix the designation of the series, the number of
authorized shares of the series, dividend rights and terms, conversion rights, voting rights, redemption rights and terms, liquidation preferences and any other rights, powers, preferences and
limitations applicable to each series of preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is
required by applicable law or the rules of any stock exchange on which our securities may be listed. If the approval of our stockholders is not required for the issuance of shares of our preferred
stock, our board may determine not to seek stockholder approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>A
series of our preferred stock could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt. Our board of directors will make any
determination to issue preferred shares based upon its judgment as to the best interests of our stockholders. Our directors, in so acting, could issue preferred stock having terms that could
discourage an acquisition attempt through which an acquirer may be able to change the composition of our board of directors, including a tender offer or other transaction that some, or a majority, of
our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over the then-current market price of the stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As of April&nbsp;30, 2018, options to purchase 3,660,952 shares of our common stock at a weighted-average exercise price of $3.76 per share were
outstanding, of which options to purchase 1,619,229 shares of our common stock were exercisable, at a weighted-average exercise price of $5.26 per share. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As of April&nbsp;30, 2018, we had outstanding warrants to purchase shares of our common stock exercisable for an aggregate of 24,566 shares of our common
stock at an exercise price of $12.2114 per share. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our second amended and restated investor rights agreement, or the Investor Rights Agreement, provides certain holders of our preferred stock, including some
of our directors and 5% stockholders and their respective affiliates and entities affiliated with our officers and directors, the right to require us to file registration statements under the
Securities Act covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. In addition, the holders of warrants to purchase shares
of our preferred stock have rights under those warrants to become party to the Investor Rights Agreement following exercise of the warrants, following which they will have, with respect to the shares
acquired on exercise of the warrants, the
same rights to require us to register the shares as the other investor parties to the Investor Rights Agreement. After registration pursuant to these rights, these shares will become freely tradable
without restriction under the Securities Act in the public market, subject to volume limitations applicable to affiliates. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand Registration Rights  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Subject to specified limitations set forth in the Investor Rights Agreement, at any time the holders of a majority of then outstanding registrable securities,
as defined in the Investor Rights Agreement, acting </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=27,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=899836,FOLIO='24',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>together,
may demand in writing that we register their registrable securities under the Securities Act so long as the total amount of registrable shares requested to be registered has an anticipated
aggregate offering price to the public, net of selling expenses, of least $10.0&nbsp;million. We are not obligated to file&nbsp;a registration statement pursuant to this demand provision on more
than two occasions, subject to specified exceptions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
addition, at any time when we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3 under the Securities Act, subject to specified limitations, the holders of at least 35% of the
registrable securities then outstanding may demand in writing that we register on Form&nbsp;S-3 registrable shares held by them so long as the total amount of registrable shares requested to be
registered has an anticipated aggregate offering price to the public, net of selling expenses, of least $1.0&nbsp;million. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Incidental Registration Rights  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>If we propose to file&nbsp;a registration statement to register any of our securities under the Securities Act, either for our own account or for the
account of any of our stockholders that are not holders of registrable shares, solely for cash and on a form that would also permit the registration of registrable shares, the holders of our
registrable shares are entitled to notice of registration and,
subject to specified exceptions, we will be required to register the registrable shares then held by them that they request that we register. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Pursuant to the Investor Rights Agreement, we are required to pay all registration expenses, including registration fees, printing expenses, fees and
disbursements of our counsel and accountants and reasonable fees and disbursements of one counsel representing the selling stockholders, other than any underwriting discounts and commissions, related
to any demand or incidental registration. The Investor Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in
the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions in the registration
statement attributable to them. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Effects of Delaware Law and Our Charter and By-laws  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Delaware law, our certificate of incorporation and our by-laws contain provisions that could have the effect of delaying, deferring or discouraging another
party from acquiring control of us. These provisions, which are summarized below, may discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to
encourage persons seeking to acquire control of us to first negotiate with our board of directors. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Staggered Board; Removal of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our certificate of incorporation and by-laws divide our board of directors into three classes with staggered three-year terms. In addition, a director is only
able to be removed for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in an annual election of directors. Any
vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, can only be filled by vote of a majority of our directors then in office. The
classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party
from seeking to acquire, control of our company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=28,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=732217,FOLIO='25',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Action by Written Consent; Special Meetings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or
special meeting of such holders and may not be effected by any consent in writing by such holders. Our certificate of incorporation and by-laws also provide that, except as otherwise required by law,
special meetings of our stockholders can only be called by our chairman of the board, our Chief Executive Officer or our board of directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advance Notice Requirements for Stockholder Proposals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our by-laws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed
nominations of persons for election to our board of directors. Stockholders at an annual meeting are only able to consider proposals or nominations specified in the notice of meeting or brought before
the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely
written notice in proper form to our secretary of the stockholder's intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder
meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware Business Combination Statute  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware. Subject to certain exceptions, Section&nbsp;203 prevents a
publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for three years following the date that the person became an interested stockholder,
unless the interested stockholder attained such
status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A "business combination" includes, among other things, a merger or
consolidation involving us and the "interested stockholder" and the sale of more than 10% of our assets. In general, an "interested stockholder" is any entity or person beneficially owning 15% or more
of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment of Certificate of Incorporation and By-laws  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The General Corporation Law of the State of Delaware provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter
is required to amend a corporation's certificate of incorporation or by-laws, unless a corporation's certificate of incorporation or by-laws, as the case may be, requires a greater percentage. Our
by-laws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to
cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of
directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described above under "&nbsp;&#150; Staggered
Board; Removal of Directors" and "&nbsp;&#150; Stockholder Action by Written Consent; Special Meetings." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exclusive Forum Selection  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of
Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=29,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=966733,FOLIO='26',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>exclusive
forum for (1)&nbsp;any derivative action or proceeding brought on behalf of our company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors,
officers or employees to our company or our stockholders, (3)&nbsp;any action asserting a claim against our company arising pursuant to any provision of the General Corporation Law of the State of
Delaware or our
certificate of incorporation or by-laws, or (4)&nbsp;any action asserting a claim against our company governed by the internal affairs doctrine. Although our certificate of incorporation contains
the choice of forum provision described above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing on The Nasdaq Global Market  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our common stock is listed on the Nasdaq Global Market under the symbol "CATB." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized but Unissued Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any
limitations imposed by the listing requirements of the Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit
plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy
contest, tender offer, merger or otherwise. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=30,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=559805,FOLIO='27',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49601_description_of_securities_we_are_offering"> </A>
<A NAME="toc_dg49601_2"> </A>
<BR></FONT><FONT SIZE=3><B>  DESCRIPTION OF SECURITIES WE ARE OFFERING  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We are offering $30,000,000 of Common Units, each Common Unit consisting of one share of our common stock and one Warrant. We are also
offering to those purchasers, if any, whose purchase of Common Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if the
purchaser so chooses, Pre-funded Units in lieu of Common Units that would otherwise result in the purchaser's beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our
outstanding common stock, each Pre-funded Unit consisting of one Pre-Funded Warrant and one Warrant. For each Pre-funded Unit we sell, the number of Common Units we are offering will be decreased on a
one-for-one basis. Common Units and Pre-funded Units will not be issued or certificated. The shares of common stock or Pre-funded Warrants, as the case may be, and the Warrants included in the Common
Units or the Pre-funded Units, can only be purchased together in this offering, but the securities contained in the Common Units or Pre-funded Units will be issued separately and will be immediately
separable upon issuance. We are also registering the shares of common stock included in the Common Units and the shares of common stock issuable from time to time upon exercise of the Pre-funded
Warrants included in Pre-funded Units and Warrants included in the Common Units and the Pre-funded Units offered hereby. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-Funded Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The following summary of certain terms and provisions of the Pre-funded Warrants included in the Pre-funded Units that are being offered hereby is not
complete and is subject to, and qualified in its entirety by, the provisions of the Pre-funded Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus
forms&nbsp;a part. Prospective investors should carefully review the terms and provisions of the form of Pre-funded Warrant for a complete description of the terms and conditions of the Pre-funded
Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Duration and Exercise Price  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Each Pre-funded Warrant offered hereby will have an initial exercise price per share equal to $0.01. The Pre-funded Warrants will be immediately exercisable
and may be exercised at
any time until the Pre-funded Warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock
dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The Pre-funded Warrants will be issued separately from the accompanying Warrants included
in the Pre-funded Units. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercisability  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The Pre-funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice
accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its
affiliates) may not exercise any portion of a Pre-funded Warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at
least 61&nbsp;days' prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder's Pre-funded Warrants up to 9.99% of the
number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-funded Warrants.
Purchasers of Pre-funded Units in this offering </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=31,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=328060,FOLIO='28',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
also elect prior to the issuance of the Pre-funded Units to have the initial exercise limitation set at 9.99% of our outstanding common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cashless Exercise  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>If, at the time a holder exercises its Pre-funded Warrants, a registration statement registering the issuance of the shares of common stock underlying the
Pre-funded Warrants under the Securities Act of 1933, as amended, or the Securities Act, is not then effective or available for the issuance of such shares, then in lieu of making the cash payment
otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net
number of shares of common stock determined according to a formula set forth in the Pre-funded Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transferability  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Subject to applicable laws, a Pre-funded Warrant may be transferred at the option of the holder upon surrender of the Pre-funded Warrant to us together with
the appropriate instruments of transfer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fractional Shares  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>No fractional shares of common stock will be issued upon the exercise of the Pre-funded Warrants. Rather, the number of shares of common stock to be issued
will be rounded to the nearest whole number. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trading Market  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>There is no trading market available for the Pre-funded Warrants on any securities exchange or nationally recognized trading system. The common stock issuable
upon exercise of the Pre-funded Warrants is currently listed on the Nasdaq Global Market. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Right as a Stockholder  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Except as otherwise provided in the Pre-funded Warrants or by virtue of such holder's ownership of shares of our common stock, the holders of the Pre-funded
Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Pre-funded Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fundamental Transaction  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In the event of a fundamental transaction, as described in the Pre-funded Warrants and generally including any reorganization, recapitalization or
reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the
acquisition of at least 50% of our outstanding common stock, or any person or group becoming the beneficial owner of at least 50% of the voting power represented by our outstanding common stock, the
holders of the pre-funded warrants will be entitled to receive upon exercise of the Pre-funded Warrants the kind and amount of securities, cash or other property that the holders would have received
had they exercised the Pre-funded Warrants immediately prior to such fundamental transaction. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrants for Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The following summary of certain terms and provisions of the Warrants included in the Common Units and the Pre-funded Units that are being offered hereby is
not complete and is subject to, and qualified </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=32,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=500019,FOLIO='29',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>in
its entirety by, the provisions of the Warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms&nbsp;a part. Prospective investors should
carefully review the terms and provisions of the form of Warrant for a complete description of the terms and conditions of the Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Duration and Exercise Price  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Each Warrant included in the Common Units and the Pre-funded Units offered hereby will have an initial exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The
Warrants will be immediately exercisable
and will expire on the fifth anniversary the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of
stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The Warrants will be issued separately from the common stock included in the Common
Units, or the Pre-funded Warrants included in the Pre-funded Units, as the case may be. A Warrant to purchase one share of our common stock will be included in each Common Unit or Pre-funded Unit
purchased in this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cashless Exercise  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>If, at the time a holder exercises its Warrants, a registration statement registering the issuance of the shares of common stock underlying the Warrants under
the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of
the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set
forth in the Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercisability  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by
payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed above). A holder (together with its affiliates) may
not exercise any portion of a Warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61&nbsp;days'
prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder's Warrants up to 9.99% of the number of shares of our common stock
outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. Purchasers of Warrants in this offering may also
elect prior to the issuance of Warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fractional Shares  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>No fractional shares of common stock will be issued upon the exercise of the Warrants. Rather, the number of shares of common stock to be issued will be
rounded to the nearest whole number. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transferability  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Subject to applicable laws, a Warrant may be transferred at the option of the holder upon surrender of the Warrant to us together with the appropriate
instruments of transfer. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=33,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=586966,FOLIO='30',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_dg49601_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exchange Listing  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We do not intend to list the Warrants on any securities exchange or nationally recognized trading system. The common stock issuable upon exercise of the
Warrants is currently listed on the Nasdaq Global Market. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Right as a Stockholder  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Except as otherwise provided in the Warrants or by virtue of such holder's ownership of shares of our common stock, the holders of the Warrants do not have
the rights or
privileges of holders of our common stock, including any voting rights, until they exercise their Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fundamental Transaction  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification of
our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of at least
50% of our outstanding common stock, or any person or group becoming the beneficial owner of at least 50% of the voting power represented by our outstanding common stock, the holders of the Warrants
will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately
prior to such fundamental transaction. In addition, in the event of a fundamental transaction which is approved by our Board, the holders of the Warrants have the right to require us or a successor
entity to redeem the Warrants for cash in the amount of the Black-Scholes value of the unexercised portion of the Warrants on the date of the consummation of the fundamental transaction. In the event
of a fundamental transaction which is not approved by our Board, the holders of the Warrants have the right to require us or a successor entity to redeem the Warrants for the consideration paid in the
fundamental transaction in the amount of the Black Scholes value of the unexercised portion of the Warrants on the date of the consummation of the fundamental transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=34,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=290489,FOLIO='31',FILE='DISK103:[18ZBT1.18ZBT49601]DG49601A.;11',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di49601_1_32"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49601_material_u.s._federal_tax_cons__mat04125"> </A>
<A NAME="toc_di49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  MATERIAL U.S. FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF OUR COMMON STOCK, PRE-FUNDED WARRANTS AND WARRANTS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The following discussion describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our
common stock, Pre-funded Warrants and Warrants acquired in this offering. This discussion is based on the current provisions of the Internal Revenue Code of 1986, as amended, referred to as the Code,
existing and proposed U.S. Treasury regulations promulgated thereunder, and administrative rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time,
possibly with retroactive effect. No ruling has been or will be sought from the Internal Revenue Service, or IRS, with respect to the matters discussed below, and there can be no assurance the IRS
will not take a contrary position regarding the tax consequences of the acquisition, ownership or disposition of our common stock, Pre-funded Warrants or Warrants, or that any such contrary position
would not be sustained by a court. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
assume in this discussion that the shares of our common stock, Pre-funded Warrants and Warrants will be held as capital assets (generally, property held for investment). This discussion does not
address all aspects of U.S. federal income taxes, does not discuss the potential application of the Medicare contribution tax, the alternative minimum tax and does not deal with state or local taxes,
U.S. federal gift and estate tax laws, except as specifically provided below with respect to non-U.S. holders, or any non-U.S. tax consequences that may be relevant to holders in light of their
particular circumstances. This discussion also does not address the special tax rules applicable to particular holders, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> brokers or dealers in securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> tax-exempt organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pension plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulated investment companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> owners that hold our common stock, Pre-funded Warrants or Warrants as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> controlled foreign corporations, passive foreign investment companies, or corporations that accumulate earnings to avoid U.S. federal income
tax; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain U.S. expatriates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>In
addition, this discussion does not address the tax treatment of partnerships or other pass-through entities or persons who hold our common stock, Pre-funded Warrants or Warrants through
partnerships or other entities which are pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our common stock, Pre-funded
Warrants or Warrants should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock, Pre-funded Warrants or Warrants through a
partnership or other pass-through entity, as applicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>This discussion of U.S. federal income tax considerations is for general information purposes only and is not tax advice. Prospective investors should consult their own tax
advisors regarding the U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding and disposing of our common stock, Pre-funded Warrants and
Warrants.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=97368,FOLIO='32',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>For
the purposes of this discussion, a "U.S. Holder" means a beneficial owner of our common stock, Pre-funded Warrants or Warrants that is for U.S. federal income tax purposes (a)&nbsp;an individual
citizen or resident of the United States, (b)&nbsp;a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the
United States, any state thereof or the District of Columbia, (c)&nbsp;an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d)&nbsp;a trust if it
(1)&nbsp;is subject to the primary supervision of a court within the United States and one or more U.S. persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) have the authority to
control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. A "Non-U.S. Holder" is, for U.S.
federal income tax purposes, a beneficial owner of common stock, Pre-funded Warrants or Warrants that is not a U.S. Holder or a partnership for U.S. federal income tax purposes. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Cuts and Jobs Act  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Under tax legislation signed into law in December 2017 commonly known as the Tax Cuts and Jobs Act of 2017, U.S. Holders that use an accrual method of
accounting for tax purposes and have certain financial statements generally will be required to include certain amounts in income no later than the time such amounts are taken into account as revenue
in such financial statements. The application of this rule thus may require the accrual of income earlier than would be the case under the general tax rules described below, although the precise
application of this rule is unclear at this time. This rule generally will be effective for taxable years beginning after December&nbsp;31, 2017. U.S. Holders that use an accrual method of
accounting should consult with their tax advisors regarding the potential applicability of this legislation to their particular situation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Allocation of Purchase Price of Common Unit and Pre-funded Unit  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>For U.S. federal income tax purposes, each Common Unit and Pre-funded Unit will be treated as an "investment unit" consisting of one share of common stock and
one Pre-funded Warrant, as applicable, and a warrant to acquire one share of our common. The purchase price for each investment unit will be allocated between these two components in proportion to
their relative fair market values at the time the unit is purchased by the holder. This allocation of the purchase price for each unit will establish the holder's initial tax basis for U.S. federal
income tax purposes in the share of common stock or Pre-funded Warrant, as applicable, and the Warrant included in each unit. The separation of the share of common stock or Pre-funded Warrant, as
applicable, and the Warrant included in each unit should not be a taxable event for U.S. federal income tax purposes. Each holder should consult his, her or its own tax advisor regarding the
allocation of the purchase price for a unit. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Treatment of Pre-funded Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Although it is not entirely free from doubt, a Pre-funded Warrant should be treated as a share of our common stock for U.S. federal income tax purposes and a
holder of Pre-funded Warrants should generally be taxed in the same manner as a holder of common stock as described below. Accordingly, upon exercise, the holding period of a Pre-funded Warrant should
carry over to the share of common stock received. Similarly, the tax basis of the Pre-funded Warrant should carry over to the share of common stock received upon exercise increased by the exercise
price of $0.01. Each holder should consult his, her or its own tax advisor regarding the risks associated with the acquisition of a unit pursuant to this offering (including potential alternative
characterizations). The
balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=659583,FOLIO='33',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Considerations Applicable to U.S. Holders  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercise and Expiration of Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In general, a U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon exercise of a Warrant. The U.S. Holder will take a tax
basis in the shares acquired on the exercise of a Warrant equal to the exercise price of the Warrant, increased by the U.S. Holder's adjusted tax basis in the Warrant exercised (as determined pursuant
to the rules discussed above). The U.S. Holder's holding period in the shares of our common stock acquired on exercise of the Warrant will begin on the date of exercise of the Warrant, and will not
include any period for which the U.S. Holder held the Warrant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
certain limited circumstances, a U.S. Holder may be permitted to undertake a cashless exercise of Warrants into our common stock. The U.S. federal income tax treatment of a cashless exercise of
Warrants into our common stock is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a Warrant described in the preceding paragraph. U.S.
Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of Warrants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
lapse or expiration of a Warrant will be treated as if the U.S. Holder sold or exchanged the Warrant and recognized a capital loss equal to the U.S. Holder's tax basis in the Warrant. The
deductibility of capital losses is subject to limitations. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Adjustments to and Distributions on Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Under Section&nbsp;305 of the Code, an adjustment to the number of shares of common stock issued on the exercise of the Warrants, or an adjustment to the
exercise price of the Warrants, may be treated as a constructive distribution to a U.S. Holder of the Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S.
Holder's proportionate interest in our "earnings and profits" or assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash
or other property to our shareholders). An adjustment made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution should generally not be considered to result
in a constructive distribution. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property to the holders of Warrants. In certain
circumstances, if we were to make a distribution in cash or other property with respect to our common stock after the issuance of the Warrants, then we may make a corresponding distribution to a
Warrant holder. The taxation of a distribution received with respect to a Warrant is unclear. It is possible such a distribution would be treated as a distribution (or constructive distribution),
although other treatments are possible. For more information regarding the tax considerations related to distributions, see the discussion below regarding "Distributions". U.S. Holders should consult
their tax advisors regarding the proper treatment of any adjustments to the Warrants and any distributions with respect to the Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As discussed above, we currently anticipate that we will retain future earnings, if any, to finance the growth and development of our business and do not
intend to pay cash dividends in respect of our common stock in the foreseeable future. In the event that we do make distributions on our common stock or Pre-funded Warrants to a U.S. Holder, those
distributions generally will constitute dividends for U.S. tax purposes to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax
principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=849104,FOLIO='34',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>but
not below zero, a U.S. Holder's adjusted tax basis in our common stock or Pre-funded Warrant, as applicable. Any remaining excess will be treated as gain realized on the sale or exchange of our
common stock or Pre-funded Warrant as described below under the section titled "&nbsp;&#150; Disposition of Our Common Stock, Pre-Funded Warrants or Warrants." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Disposition of Our Common Stock, Pre-Funded Warrants or Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Upon a sale or other taxable disposition of our common stock, Pre-funded Warrants or Warrants, a U.S. Holder generally will recognize capital gain or loss in
an amount equal to the difference between the amount realized and the U.S. Holder's adjusted tax basis in the common stock, Pre-funded Warrants or Warrants. Capital gain or loss will constitute
long-term capital gain or loss if the U.S. Holder's holding period for the common stock, Pre-funded Warrants or Warrants exceeds one year. The deductibility of capital losses is subject to certain
limitations. U.S. Holders who recognize losses with respect to a disposition of our common stock, Pre-funded Warrants or Warrants should consult their own tax advisors regarding the tax treatment of
such losses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Information reporting requirements generally will apply to payments of dividends (including constructive dividends) on the common stock, Pre-funded Warrants
and Warrants and to the proceeds of a sale or other disposition of common stock, Pre-funded Warrants and Warrants paid by us to a U.S. Holder unless such U.S. Holder is an exempt recipient, such as a
corporation. Backup withholding will apply to those payments if the U.S. Holder fails to provide the holder's taxpayer identification number, or certification of exempt status, or if the holder
otherwise fails to comply with applicable requirements to establish an exemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Backup
withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against the U.S. Holder's U.S. federal income tax
liability provided the required information is timely furnished to the IRS. U.S. Holders should consult their own tax advisors regarding their qualification for exemption from information reporting
and backup withholding and the procedure for obtaining such exemption. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Considerations Applicable To Non-U.S. Holders  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercise and Expiration of Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In general, a Non-U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon the exercise of Warrants into shares of common stock.
The U.S. federal income tax treatment of a cashless exercise of Warrants into our common stock is unclear. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding the U.S. federal
income tax consequences of a cashless exercise of Warrants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
expiration of a Warrant will be treated as if the Non-U.S. Holder sold or exchanged the Warrant and recognized a capital loss equal to the Non-U.S. Holder's tax basis in the Warrant. However, a
Non-U.S. Holder will not be able to utilize a loss recognized upon expiration of a Warrant against the Non-U.S. Holder's U.S. federal income tax liability unless the loss is effectively connected with
the Non-U.S. Holder's conduct of a trade or business within the United States (and, if an income tax treaty applies, is attributable to a permanent establishment or fixed base in the United States) or
is treated as a U.S.-source loss and the Non-U.S. Holder is present 183&nbsp;days or more in the taxable year of disposition and certain other conditions are met. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=787989,FOLIO='35',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Adjustments to and Distributions on Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As described under "&nbsp;&#150; U.S. Holders&nbsp;&#150; Certain Adjustments to Warrants", an adjustment to the Warrants could result in a
constructive distribution to a Non-U.S. Holder, which would be treated as described under "Distributions below, and the tax treatment of distributions on the warrants is unclear. Any resulting
withholding tax attributable to deemed dividends would be collected from other amounts payable or distributable to the Non-U.S. Holder. Non-U.S. Holders should consult their tax advisors regarding the
proper treatment of any adjustments to and distributions on the Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>As discussed above, we currently anticipate that we will retain future earnings, if any, to finance the growth and development of our business and do not
intend to pay cash dividends in respect of our common stock in the foreseeable future. In the event that we do make distributions on our common stock or Pre-funded Warrants to a Non-U.S. Holder, those
distributions generally will constitute dividends for U.S. federal income tax purposes as described in "&nbsp;&#150; U.S. Holders&nbsp;&#150; Distributions". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Any
distribution (including constructive distributions) on our common stock or Pre-funded Warrants that is treated as a dividend paid to a Non-U.S. Holder that is not effectively connected with the
holder's conduct of a trade or business in the United States will generally be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty
between the United States and the Non-U.S. Holder's country of residence. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally will be required to provide the applicable
withholding agent with a properly executed IRS Form&nbsp;W-8BEN, IRS Form&nbsp;W-8BEN-E or other appropriate form, certifying the Non-U.S. Holder's entitlement to benefits under that treaty. Such
form must be provided prior to the payment of dividends and must be updated periodically. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder's behalf,
the holder will be required to provide appropriate documentation to such agent. The holder's agent may then be required to provide certification to the applicable withholding agent, either directly or
through other intermediaries. If you are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to
obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
generally are not required to withhold tax on dividends paid (or constructive dividends deemed paid) to a Non-U.S. Holder that are effectively connected with the holder's conduct of a trade or
business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that the holder maintains in the United States) if a
properly executed IRS Form&nbsp;W-8ECI, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to the applicable
withholding agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A
corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional "branch profits tax," which is imposed, under certain circumstances, at a rate of 30% (or such
lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder's effectively connected earnings and profits, subject to certain adjustments. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>See
also the sections below titled "&nbsp;&#150; Backup Withholding and Information Reporting" and "&nbsp;&#150; Foreign Accounts" for additional withholding rules that may apply to
dividends paid to certain foreign financial institutions or non-financial foreign entities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=470834,FOLIO='36',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Disposition of Our Common Stock, Pre-Funded Warrants or Warrants  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Subject to the discussions below under the sections titled "&nbsp;&#150; Backup Withholding and Information Reporting" and "&nbsp;&#150;
Foreign Accounts," a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain realized on a sale or other disposition of our common stock,
Pre-funded Warrant or Warrants unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the gain is effectively connected with the Non-U.S. Holder's conduct of a trade or business in the United States, and if an applicable income
tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States; in these cases, the Non-U.S. Holder will be taxed on
a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and if the Non-U.S. Holder is a corporation, an additional branch profits tax at a rate of 30%, or a
lower rate as may be specified by an applicable income tax treaty, may also apply; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Non-U.S. Holder is a nonresident alien present in the United States for 183&nbsp;days or more in the taxable year of the disposition and
certain other requirements are met, in which case the Non-U.S. Holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States
and such holder's country of residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the Non-U.S. Holder, if any; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our common stock constitutes a U.S. real property interest because we are, or have been at any time during the five-year period preceding such
disposition (or the Non-U.S. Holder's holding period of the common stock, Pre-funded Warrants or Warrants, if shorter), a "U.S. real property holding corporation," unless our common stock is regularly
traded on an established securities market and the Non-U.S. Holder held no more than 5% of our outstanding common stock, directly or indirectly, during the shorter of the five-year period ending on
the date of the disposition or the period that the Non-U.S. Holder held our common stock. Special rules may apply to the determination of the 5% threshold in the case of a holder of a Pre-funded
Warrant or Warrant. Non-U.S. Holders are urged to consult their own tax advisors regarding the effect of holding our Pre-funded Warrants or Warrants on the calculation of such 5% threshold. Generally,
a corporation is a "U.S. real property holding corporation" if the fair market value of its "U.S. real property interests" (as defined in the Code and applicable regulations) equals or exceeds 50% of
the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are
not currently, and we do not anticipate becoming, a "U.S. real property holding corporation" for U.S. federal income tax purposes. No assurance can be provided that our common stock will be regularly
traded on an established securities market for purposes of the rules described above. Non-U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax considerations
that could result if we are, or become, a "U.S. real property holding corporation". </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>See
the sections titled "&nbsp;&#150; Backup Withholding and Information Reporting" and "&nbsp;&#150; Foreign Accounts" for additional information regarding withholding rules that
may apply to proceeds of a disposition of our common stock, Pre-funded Warrants or Warrants paid to foreign financial institutions or non-financial foreign entities. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Estate Tax  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Common stock or Pre-funded Warrants owned or treated as owned by an individual who is not a citizen or resident of the United States (as specially defined for
U.S. federal estate tax purposes) at the time of death will be included in the individual's gross estate for U.S. federal estate tax purposes and, therefore, may be subject to U.S. federal estate tax,
unless an applicable estate tax or other treaty </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=22934,FOLIO='37',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_38"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>provides
otherwise. The foregoing may also apply to Warrants. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding the U.S. federal estate tax consequences of the ownership or
disposition of shares of our common stock, Pre-funded Warrants and Warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Backup Withholding and Information Reporting  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We must report annually to the IRS and to each Non-U.S. Holder the gross amount of the distributions (including constructive distributions) on our common
stock, Pre-funded Warrants or Warrants paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. Holders may have to comply with specific certification procedures
to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate, currently 24%, with respect to dividends (or constructive
dividends) on our common stock, Pre-funded Warrants or Warrants. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form&nbsp;W-8BEN (or other applicable
Form&nbsp;W-8) or otherwise meets documentary evidence requirements for establishing that it is a Non-U.S. Holder, or otherwise establishes an exemption. Dividends paid to Non-U.S. Holders subject
to withholding of U.S. federal income tax, as described above under the heading "Dividends," will generally be exempt from U.S. backup withholding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Information
reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock, Pre-funded Warrants or Warrants by a Non-U.S. Holder effected by or through the
U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a Non-U.S. Holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally,
information reporting and backup withholding will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S.
office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in
a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. Holders should consult their own tax advisors regarding the application of the information reporting and backup
withholding rules to them. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Copies
of information returns may be made available to the tax authorities of the country in which the Non-U.S. Holder resides or is incorporated under the provisions of a specific treaty or
agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a Non-U.S. Holder can be refunded or credited against the Non-U.S. Holder's U.S.
federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Accounts  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The Foreign Account Tax Compliance Act, or FATCA, generally imposes a 30% withholding tax on dividends (including constructive dividends) on, and gross
proceeds from the sale or other disposition of, our common stock, Pre-funded Warrants and Warrants if paid to a non-U.S. entity unless (i)&nbsp;if the non-U.S. entity is a "foreign financial
institution," the non-U.S. entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the non-U.S. entity is not a "foreign financial institution,"
the non-U.S. entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the non-U.S. entity is otherwise exempt under FATCA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Withholding
under FATCA generally (1)&nbsp;applies to payments of dividends (including constructive dividends) on our common stock, Pre-funded Warrants and Warrants and (2)&nbsp;will apply to
payments of gross proceeds from a sale or other disposition of our common stock, Pre-funded Warrants and Warrants made after December&nbsp;31, 2018. An intergovernmental agreement between the United
States and an applicable foreign country may modify the requirements described in this section. Under certain circumstances, a holder may be eligible for refunds or credits of the tax. Holders should
consult their </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1023713,FOLIO='38',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<A NAME="page_di49601_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>own
tax advisors regarding the possible implications of FATCA on their investment in our common stock, Pre-funded Warrants or Warrants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>The preceding discussion of material U.S. federal tax considerations is for information only. It is not tax advice. Prospective investors should consult their own tax advisors
regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock, Pre-funded Warrants or Warrants, including the consequences
of any proposed changes in applicable laws.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=42,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=922931,FOLIO='39',FILE='DISK103:[18ZBT1.18ZBT49601]DI49601A.;14',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk49601_1_40"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk49601_underwriting"> </A>
<A NAME="toc_dk49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  UNDERWRITING  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We entered into an underwriting agreement with the underwriters named below
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. Oppenheimer &amp; Co.
Inc. is acting as the
sole book-running manager and representative of the underwriters. The underwriting agreement provides for the purchase of a specific number of units by each of the underwriters. The underwriters'
obligations are several, which means that each underwriter is required to purchase a specified number of units, but is not responsible for the commitment of any other underwriter to purchase units.
Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase the number of Common Units and Pre-funded Units set forth opposite its name below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Underwriter </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Common Units </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Pre-Funded Units </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Oppenheimer&nbsp;&amp;&nbsp;Co.&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>We
expect that delivery of the Common Units and/or Pre-funded Units will be made to investors on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (such settlement date being referred to as "T+2") against immediately
available funds. The underwriters may, in their discretion, allow one or more purchasers to settle on a date that is later than T+2. Under Rule&nbsp;15c6-1 of the Exchange Act, trades in the
secondary market are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. To prevent a failed settlement, purchasers that elect to settle on a date
that is later than T+2 shall not be permitted to trade such securities in advance of the applicable settlement date, and should consult with their advisors in connection therewith. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
units offered hereby are expected to be ready for delivery on or about&nbsp;&nbsp;&nbsp;&nbsp;, 2018 against payment in immediately available funds. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
underwriters are offering the units subject to various conditions and may reject all or part of any order. The representative of the underwriters has advised us that the underwriters propose
initially to offer the Common Units and the Pre-funded Units, as the case may be, to the public at the public offering prices set forth on the cover page of this prospectus and to dealers at a price
less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of unit to brokers and dealers. After the units are released for sale to the public, the representative may change the offering
price, the
concession, and other selling terms at various times. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
following table provides information regarding the amount of the discount and commissions to be paid to the underwriters by us, before expenses: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per<BR>
Common<BR>
Unit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per<BR>
Pre-Funded<BR>
Unit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discount and commissions</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>We
have agreed, subject to certain conditions, limitations and exceptions, to provide the Oppenheimer&nbsp;&amp;&nbsp;Co.&nbsp;Inc. with a right of first refusal to act as underwriter, initial
purchaser, placement agent or selling agent, as the case may be, on any equity financing that may be undertaken by us on or
before&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=249809,FOLIO='40',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
estimate that our total expenses of the offering, excluding the estimated underwriting discount and commissions, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which includes $125,000 of fees and expenses for which
we
have agreed to reimburse the underwriters. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>We
and our officers and directors have agreed to a 90-day "lock-up" with respect to shares of our common stock and other of our securities that they beneficially own, including securities that are
convertible into shares of common stock and securities that are exchangeable or exercisable for shares of common stock. This means that, subject to certain exceptions, for a period of 90&nbsp;days
following the date of this prospectus, we and such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of
Oppenheimer&nbsp;&amp;&nbsp;Co.&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
underwriters have advised us that they do not intend to conduct any stabilization or over-allotment activities in connection with this offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Electronic
Delivery of Prospectus: A prospectus in electronic format may be delivered to potential investors by one or more of the underwriters participating in this offering. The prospectus in
electronic format will be identical to the paper version of such prospectus. Other than the prospectus in electronic format, the information on any underwriter's website and any information contained
in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus forms&nbsp;a part. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
underwriters and their affiliates have provided in the past and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services
for us and our affiliates in the ordinary course of their business, for which they may receive customary fees and commissions. In addition, from time to time, the underwriters and their affiliates may
effect transactions for their own accounts or the accounts of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may
do so in the future. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the European Economic Area  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member state), with effect from
and including the date on which the Prospectus Directive is implemented in that relevant member state (the relevant
implementation date), an offer of our securities described in this prospectus may not be made to the public in that relevant member state other than:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or
legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant Dealer or
Dealers nominated by us for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>provided
that no such offer of shares of our securities shall require us or the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>For
purposes of this provision, the expression an "offer of securities to the public" in any relevant member state means the communication in any form and by any means of sufficient information on the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=664324,FOLIO='41',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>terms
of the offer and our securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities, as the expression may be varied in that member state by any
measure implementing the Prospectus Directive in that member state, the expression "Prospectus Directive" means Directive&nbsp;2003/71/EC (and amendments thereto, including the 2010 PD Amending
Directive, to the extent implemented in the relevant member state) and includes any relevant implementing measure in the relevant member state, and the expression "2010 PD Amending Directive" means
Directive&nbsp;2010/73/EU. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
and the underwriters have not authorized and do not authorize the making of any offer of our securities through any financial intermediary on our or their behalf, other than offers made by the
underwriters with a view to the final placement of our securities as contemplated in this prospectus. Accordingly, no purchaser of our securities, other than the underwriters, is authorized to make
any further offer of our securities on behalf of us or the underwriters. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the United Kingdom  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of
Article&nbsp;2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, or the Order, or (ii)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the
Order (each such person being referred to as a relevant person). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This
prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom.
Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Canada  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This document constitutes an "exempt offering document" as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been
filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the securities described herein (the "Securities"). No securities commission or
similar regulatory authority in Canada has reviewed or in any way passed upon this document or on the merits of the Securities and any representation to the contrary is an offence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Canadian investors are advised that this document has been prepared in reliance on section&nbsp;3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts
("NI&nbsp;33-105"). Pursuant to section&nbsp;3A.3 of NI&nbsp;33-105, this document is exempt from the requirement to provide investors with certain conflicts of interest disclosure pertaining to
"connected issuer" and/or "related issuer" relationships as would otherwise be required pursuant to subsection&nbsp;2.1(1) of NI&nbsp;33-105.</B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Resale Restrictions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The offer and sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement to prepare and file&nbsp;a
prospectus under applicable Canadian securities laws. Any resale of Securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws,
which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus
requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=45,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=353281,FOLIO='42',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>requirements
granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the Securities outside of Canada. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Representations of Purchasers  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Each Canadian investor who purchases the securities will be deemed to have represented to the issuer and to each dealer from whom a purchase confirmation is
received, as applicable, that the investor (i)&nbsp;is purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only
and not with a view to resale or redistribution; (ii)&nbsp;is an "accredited investor" as such term is defined in section&nbsp;1.1 of National Instrument&nbsp;45-106 Prospectus Exemptions
("NI&nbsp;45-106") or, in Ontario, as such term is defined in section&nbsp;73.3(1) of the Securities Act (Ontario); and (iii)&nbsp;is a "permitted client" as such term is defined in
section&nbsp;1.1 of National Instrument&nbsp;31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Taxation and Eligibility for Investment  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Any discussion of taxation and related matters contained in this document does not purport to be a comprehensive description of all of the tax considerations
that may be relevant to a Canadian investor when deciding to purchase the securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made
as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the securities or with respect to the eligibility of the securities for investment by such investor under
relevant Canadian federal and provincial legislation and regulations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Rights of Action for Damages or Rescission  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum, including where
the distribution involves an "eligible foreign security" as such term is defined in Ontario Securities Commission Rule&nbsp;45-501 Ontario Prospectus and Registration Exemptions and in Multilateral
Instrument&nbsp;45-107 Listing Representation and Statutory Rights of Action Disclosure Exemptions, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights
they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a "misrepresentation" as defined under
applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed
under, and are subject to limitations and defences under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or
remedy available at law to the investor. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Language of Documents  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to
the sale of the Securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. </FONT><FONT SIZE=2><I>Par la
r&eacute;ception de ce document, chaque investisseur canadien confirme par les pr&eacute;sentes qu'il a express&eacute;ment exig&eacute; que tous les documents faisant
foi ou se rapportant de quelque mani&egrave;re que ce soit &agrave; la vente des valeurs mobili&egrave;res d&eacute;crites aux pr&eacute;sentes (incluant, pour
plus de certitude, toute confirmation d'achat ou tout avis) soient r&eacute;dig&eacute;s en anglais seulement.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=46,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=358983,FOLIO='43',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Australia  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>No prospectus or other disclosure document (as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act) in relation to our securities has
been or will be lodged with the Australian Securities&nbsp;&amp; Investments Commission, or ASIC. This document has not been lodged with ASIC and is only directed to certain categories of exempt
persons. Accordingly, if you receive this document in Australia you confirm and warrant that you are either:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant's
certificate to us which complies with the requirements of section&nbsp;708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a person associated with the company under section&nbsp;708(12) of the Corporations Act; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "professional investor" within the meaning of section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act, and to the extent that you are
unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this document is void and
incapable of acceptance; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> you warrant and agree that you will not offer any of our securities for resale in Australia within 12&nbsp;months of those securities being
issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in France  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Neither this prospectus nor any other offering material relating to our securities described in this prospectus has been submitted to the clearance procedures
of the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2> or of the competent authority of another member state of the European Economic Area
and notified to the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2>. These securities have not been offered or sold and will not be
offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to our securities has been or will
be:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> used in connection with any offer for subscription or sale of our securities to the public in France. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Such
offers, sales and distributions will be made in France only:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to qualified investors (investisseurs qualifi&eacute;s) and/or to a restricted circle of investors (cercle restreint d'investisseurs),
in each case investing for their own account, all as defined in, and in accordance with articles&nbsp;L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the French Code
mon&eacute;taire et financier; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in a transaction that, in accordance with article&nbsp;L.411-2-II-1&deg;-or-2&deg;-or 3&deg; of the French
Codemon&eacute;taire et financier and article&nbsp;211-2 of the General Regulations (</FONT><FONT SIZE=2><I>R&egrave;glement
G&eacute;n&eacute;ral</I></FONT><FONT SIZE=2>) of the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2>, does not constitute
a public offer (</FONT><FONT SIZE=2><I>appel public &agrave; l'&eacute;pargne</I></FONT><FONT SIZE=2>). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Our
securities may be resold directly or indirectly, only in compliance with articles&nbsp;L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French Code mon&eacute;taire et
financier. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=47,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=134943,FOLIO='44',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Chile  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our securities are not registered in the Securities Registry (Registro de Valores) or subject to the control of the Chilean Securities and Exchange Commission
(Superintendencia de Valores y Seguros de Chile). This prospectus and other offering materials relating to the offer of the securities do not constitute a public offer of, or an invitation to
subscribe for or purchase, the shares in the Republic of Chile, other than to individually identified purchasers pursuant to a private offering within the meaning of Article&nbsp;4 of the Chilean
Securities Market Act (Ley de Mercado de Valores) (an offer that is not "addressed to the public at large or to a certain sector or specific group of the public"). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Hong Kong  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our securities may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws
of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance (Cap. 32,
Laws of Hong Kong) and no advertisement, invitation or document relating to our securities may be issued or may be in the possession of any person for the purpose of issue (in each case whether in
Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other
than with respect to our securities which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures
Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the State of Israel  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase securities under the Israeli Securities Law,
5728&nbsp;-&nbsp;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli
Securities Law, 5728&nbsp;-&nbsp;1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the "Addressed
Investors"); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&nbsp;-&nbsp;1968, subject to
certain conditions (the "Qualified Investors"). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to
the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law,
5728&nbsp;-&nbsp;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our securities to any person within the State of Israel, other
than to Qualified Investors and up to 35 Addressed Investors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&nbsp;-&nbsp;1968. In particular, we may
request, as a condition to be offered securities, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor
falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&nbsp;-&nbsp;1968; (ii)&nbsp;which of the categories listed in the First Addendum to the
Israeli Securities Law, 5728&nbsp;-&nbsp;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law,
5728&nbsp;-&nbsp;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=48,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=556570,FOLIO='45',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
securities that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&nbsp;-&nbsp;1968: (a)&nbsp;for its own account; (b)&nbsp;for investment
purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&nbsp;-&nbsp;1968; and
(v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign
and submit a declaration containing, inter alia, the Addressed Investor's name, address and passport number or Israeli identification number. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Japan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our securities offered in this prospectus have not been and will not be registered under the Financial Instruments and Exchange Law of Japan. Our securities
have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan (including any corporation or other entity organized
under the laws of Japan), except (i)&nbsp;pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange Law and (ii)&nbsp;in compliance with any other
applicable requirements of Japanese law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Singapore  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of our securities may not be circulated or distributed, nor may our securities be offered or sold, or be made
the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the
Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in
accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in
each case subject to compliance with conditions set forth in the SFA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Where
our securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant party which is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an
individual who is an accredited investor, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>shares,
debentures and units of our securities and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six
months after that corporation or that trust has acquired our securities pursuant to an offer made under Section&nbsp;275 of the SFA except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2)
of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of our securities and debentures of that corporation or such rights and interest in that
trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of
securities or other assets, and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of the SFA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> where no consideration is or will be given for the transfer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> where the transfer is by operation of law. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=49,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=555841,FOLIO='46',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk49601_legal_matters"> </A>
<A NAME="toc_dk49601_2"> </A>
<BR></FONT><FONT SIZE=3><B>  LEGAL MATTERS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The validity of the securities offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP, Boston,
Massachusetts. Lowenstein Sandler&nbsp;LLP, New York, New York, is acting as counsel for the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk49601_experts"> </A>
<A NAME="toc_dk49601_3"> </A>
<BR></FONT><FONT SIZE=3><B>  EXPERTS  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Ernst&nbsp;&amp; Young,&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, as set forth in their report (which contains an explanatory paragraph describing the conditions that raise
substantial doubt about the Company's ability to continue as a going concern as described in Note&nbsp;1&nbsp;&#150;&nbsp;Organization and Operations to the consolidated financial
statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp;
Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk49601_where_you_can_find_more_information"> </A>
<A NAME="toc_dk49601_4"> </A>
<BR></FONT><FONT SIZE=3><B>  WHERE YOU CAN FIND MORE INFORMATION  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission, or the SEC.
Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at
www.catabasis.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus. You may also read and copy any document we file at the SEC's Public Reference
Room, 100&nbsp;F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This
prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations.
You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiary and the securities we are offering. Statements in this
prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to
these filings. You should review the complete document to evaluate these statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk49601_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_dk49601_5"> </A>
<BR></FONT><FONT SIZE=3><B>  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The SEC allows us to incorporate by reference much of the information we file with it, which means that we can disclose important information
to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Any statement contained
in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus
modifies or replaces that statement. This prospectus incorporates by reference the documents listed below (File No.&nbsp;001-37467 unless otherwise indicated), other than the portions of those
documents not deemed to be filed. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=50,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1018719,FOLIO='47',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<A NAME="page_dk49601_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Quarterly Report on Form&nbsp;10-Q for the quarterly period ended March&nbsp;31, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our definitive proxy statement on Schedule&nbsp;14A filed with the SEC on April&nbsp;26, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the information under the caption "Certain Relationships and Related Person Transactions" from our definitive proxy statements on
Schedule&nbsp;14A filed with the SEC on April&nbsp;26, 2016 and April&nbsp;26, 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Current Reports on Form&nbsp;8-K filed with the SEC on February&nbsp;13, 2018 and April&nbsp;17, 2018. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Upon
written or oral request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered a copy of the documents incorporated by
reference into this prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost by writing or
telephoning us at the following address: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Catabasis
Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>One
Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139<BR>
Telephone: 617-349-1971 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>You
also may access these filings on our Internet site at www.catabasis.com. Our web site and the information contained on that site, or connected to that site, are not incorporated into this
prospectus or the Registration Statement on Form&nbsp;S-1. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=51,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=595670,FOLIO='48',FILE='DISK103:[18ZBT1.18ZBT49601]DK49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$30,000,000 of  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Units, Each Consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Pre-funded Units, Each Consisting of a Pre-funded Warrant to Purchase One Share of<BR>
Common Stock and a Warrant to Purchase One Share of Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="39%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="39%" ALIGN="CENTER" >


  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="39%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="39%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Oppenheimer&nbsp;&amp;&nbsp;Co.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="39%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="39%" ALIGN="CENTER" >


 </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=52,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=397640,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]HO49601A.;18',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja49601_1"> </A>
<BR></FONT><FONT SIZE=3><B>  PART II  <BR>    <BR>    INFORMATION NOT REQUIRED IN PROSPECTUS  <BR>  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_item_13._other_expense__ja401993"> </A>
<A NAME="toc_ja49601_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The expenses payable by Catabasis Pharmaceuticals,&nbsp;Inc. ("we," "us," "our," the "Registrant" or the "Company") in connection with the issuance and
distribution of the securities being registered (other than underwriting discounts and commissions, if any) are set forth below. Each item listed is estimated, except for the Securities and Exchange
Commission (the "SEC") registration fee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC registration fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Industry Regulatory Authority,&nbsp;Inc. filing fee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer agent fees and expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="23%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="23%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>To
be provided by amendment. </FONT></DD></DL>
 </DIV>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja49601_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Section&nbsp;102 of the Delaware General Corporation Law (the "DGCL") permits a corporation to eliminate the personal liability of its
directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in
intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.
Our certificate of incorporation provides that no director shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any
provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Section&nbsp;145
of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the
corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an
action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be
in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of
actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the
case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other than an action by or in the right of us), by reason of the fact that he or she is or was, or has agreed to become, our director or
officer, or is or
was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or
other enterprise (all such persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys'
fees), judgments, </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=53,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=734716,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>fines
and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom if such Indemnitee acted in good faith and in a manner
he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct
was unlawful. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
certificate of incorporation also provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of
the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or
trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such
capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or
proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no
indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication
but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits
or otherwise, he or she will be indemnified by us against all expenses (including attorneys' fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If we
do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the director or executive officer to the fullest
extent permitted by law for claims arising in his or her capacity as a director or officer of our company or in connection with their service at our request for another corporation or entity. The
indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are
favorable to the director or executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or
officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
any underwriting agreement we enter into in connection with the sale of the securities being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors
and officers (as well as certain other persons) against certain liabilities arising in connection with such offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Insofar
as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended (the
"Securities Act"), we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja49601_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Set forth below is information regarding the shares of common stock and preferred stock and the warrants issued, and options granted, by us in the three years
preceding the filing of this registration statement that were not registered under the Securities Act. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrant Exercises  </I></B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
February 2016, we issued 2,917 shares of our common stock upon the exercise of warrants at an exercise price of $1.67 per share. </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=54,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=148503,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
March 2016, we issued 11,668 shares of our common stock upon the exercise of warrants at an exercise price of $1.67 per share, and 5,987 shares of our common
stock upon the cashless exercise of warrants to purchase 8,753 shares of our common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
April 2016, we issued 10,669 shares of our common stock upon the exercise of warrants at an exercise price of $1.67 per share. </FONT></DD></DL>


<P style="font-family:times;"><FONT SIZE=2>All
recipients either received adequate information about us or had access, through relationships with us, to such information. These shares of our common stock were issued in reliance upon the
exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) of the Securities Act, relative to transactions by an issuer not involving any public
offering, to the extent an exemption from such registration was required. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion of Shares of Preferred Stock  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>On June&nbsp;30, 2015, upon the closing of our initial public offering, all 116,030,239 shares of our then-outstanding redeemable convertible preferred
stock were automatically converted into 9,029,549 shares of common stock. The issuance of such shares of common stock was exempt from the registration requirements of the Securities Act, pursuant to
Section&nbsp;3(a)(9) of the Securities Act. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option Grants and Option Exercises  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Between June&nbsp;1, 2015 and August&nbsp;14, 2015, we granted options to purchase an aggregate of 217,337 shares of common stock, with exercise prices
ranging from $12.21 to $14.05 per share, to employees, directors and consultants pursuant to our 2008 equity incentive plan. Between June&nbsp;1, 2015 and August&nbsp;14, 2015, we did not issue
any shares of common stock upon the exercise of options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>No
underwriters were involved in the foregoing issuance of securities. The issuances of stock options and the shares of our common stock issued upon the exercise of the options described above were
issued pursuant to written compensatory plans or arrangements with our employees, directors and
consultants, in reliance on the exemption provided by Rule&nbsp;701 promulgated under the Securities Act, or as set forth in Section&nbsp;4(a)(2) of the Securities Act, relative to transactions by
an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or had access, through
relationships with us, to such information.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja49601_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>A list of exhibits filed with this registration statement on Form&nbsp;S-1 is set forth in the following Exhibit Index. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=55,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=71817,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_exhibit_index"> </A>
<A NAME="toc_ja49601_6"> </A>
<BR></FONT><FONT SIZE=3><B>  EXHIBIT INDEX  <BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Underwriting Agreement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465915049288/a14-26552_9ex3d1.htm">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit&nbsp;3.1 to the Registrant's
Current Report on Form&nbsp;8-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on July&nbsp;1, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465915049288/a14-26552_9ex3d2.htm">Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit&nbsp;3.2 to the Registrant's Current
Report on Form&nbsp;8-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on July&nbsp;1, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915005376/a2225036zex-4_1.htm">Specimen stock certificate evidencing the shares of common stock (incorporated by reference to Exhibit&nbsp;4.1 to the
Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on June&nbsp;11, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Pre-Funded Warrant</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Warrant</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Opinion of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_2.htm">Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on August&nbsp;27, 2014 by the Registrant to Square 1
Bank (incorporated by reference to Exhibit&nbsp;10.2 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_3.htm">Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on August&nbsp;27, 2014 by the Registrant to Midcap
Financial SBIC,&nbsp;L.P. (incorporated by reference to Exhibit&nbsp;10.3 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_4.htm">Amended and Restated 2008 Equity Incentive Plan, as amended (incorporated by reference to Exhibit&nbsp;10.4 to the
Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_5.htm">Form of Incentive Stock Option Agreement under Amended and Restated 2008 Equity Incentive Plan (incorporated by reference to
Exhibit&nbsp;10.5 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_6.htm">Form of Nonstatutory Stock Option Agreement under Amended and Restated 2008 Equity Incentive Plan (incorporated by reference
to Exhibit&nbsp;10.6 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915005376/a2225036zex-10_7.htm">2015 Stock Incentive Plan (incorporated by reference to Exhibit&nbsp;10.7 to the Registrant's Registration Statement on
Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on June&nbsp;11, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915005184/a2224803zex-10_8.htm">Form of Incentive Stock Option Agreement under 2015 Stock Incentive Plan (incorporated by reference to Exhibit&nbsp;10.8 to
the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on June&nbsp;3, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915005184/a2224803zex-10_9.htm">Form of Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan (incorporated by reference to Exhibit&nbsp;10.9
to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on June&nbsp;3, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=56,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=681984,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915005184/a2224803zex-10_22.htm">2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit&nbsp;10.22 to the Registrant's Registration
Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on June&nbsp;3, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915005376/a2225036zex-10_1.htm">Second Amended and Restated Investors' Rights Agreement, dated as of March&nbsp;17, 2015, among the Registrant and the other
parties thereto, as amended June&nbsp;10, 2015 (incorporated by reference to Exhibit&nbsp;10.1 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on June&nbsp;11,
2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_10.htm">Amended and Restated Employment Agreement, dated as of April&nbsp;7, 2010, by and between the Registrant and Jill C. Milne,
as amended (incorporated by reference to Exhibit&nbsp;10.10 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746916011175/a2227770zex-10_23.htm">Offer Letter, dated as of September&nbsp;30, 2015, by and between the Registrant and Deirdre Cunnane (incorporated by
reference to Exhibit&nbsp;10.23 to the Registrant's Annual Report on Form&nbsp;10-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on March&nbsp;15, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465916112488/a16-8603_1ex99d1.htm">Catabasis Pharmaceuticals,&nbsp;Inc. Executive Severance Benefits Plan effective April&nbsp;15, 2016 (incorporated by
reference to Exhibit&nbsp;99.1 to the Registrant's Current Report on Form&nbsp;8-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on April&nbsp;19, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_13.htm">Form of Indemnification Agreement by and between the Registrant and each of its executive officers and directors
(incorporated by reference to Exhibit&nbsp;10.13 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_14.htm">Credit and Security Agreement, dated as of August&nbsp;27, 2014, by and among the Registrant, Midcap Financial SBIC,
&nbsp;L.P., Square 1 Bank and the other lenders identified therein, as amended on March&nbsp;31, 2015 (incorporated by reference to Exhibit&nbsp;10.14 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with
the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746916011175/a2227770zex-10_24.htm">Second Amendment to Credit and Security Agreement, dated as of December&nbsp;22, 2015, by and among the Registrant, Midcap
Financial SBIC,&nbsp;L.P., Square 1 Bank and the other lenders identified therein (incorporated by reference to Exhibit&nbsp;10.24 to the Registrant's Annual Report on Form&nbsp;10-K (File No.&nbsp;001-37467) filed with the Securities and Exchange
Commission on March&nbsp;15, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_15.htm">Indenture of Lease, dated as of December&nbsp;17, 2010, by and between the Registrant and RB&nbsp;Kendall Fee,&nbsp;LLC, as
amended (incorporated by reference to Exhibit&nbsp;10.15 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465915078291/a15-18093_1ex10d1.htm">Second Amendment of Lease, dated as of July&nbsp;16, 2015, by and between the Registrant and DWF IV One Kendall,&nbsp;LLC
(incorporated by reference to Exhibit&nbsp;10.1 to the Registrant's Quarterly Report on Form&nbsp;10-Q (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on November&nbsp;11, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465916155178/a16-21209_1ex99d1.htm">Third Amendment of Lease, dated as of November&nbsp;3, 2016, by and between the Registrant and DWF IV One Kendall,&nbsp;LLC
(incorporated by reference to Exhibit&nbsp;99.1 to the Registrant's Current Report on Form&nbsp;8-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on November&nbsp;7, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=57,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=329138,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465917051037/a17-13337_1ex10d1.htm">Fourth Amendment of Lease, dated as of August&nbsp;7, 2017, by and between the Registrant and ARE-MA REGION NO. 59,
&nbsp;LLC (incorporated by reference to Exhibit&nbsp;10.1 to the Registrant's Quarterly Report on Form&nbsp;10-Q (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on August&nbsp;10, 2017)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_19.htm">Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on March&nbsp;31, 2015 to Square&nbsp;1 Bank
(incorporated by reference to Exhibit&nbsp;10.19 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_20.htm">Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on March&nbsp;31, 2015 to Midcap Financial Trust
(incorporated by reference to Exhibit&nbsp;10.20 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746915004732/a2223775zex-10_21.htm">Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on March&nbsp;31, 2015 to Flexpoint MCLS Holdings,
&nbsp;LLC (incorporated by reference to Exhibit&nbsp;10.21 to the Registrant's Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-204144) filed with the Securities and Exchange Commission on May&nbsp;13, 2015)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465916120478/a16-6672_1ex10d2.htm">Summary of Non-employee Director Compensation Program (incorporated by reference to Exhibit&nbsp;10.2 to the Registrant's
Quarterly Report on Form&nbsp;10-Q (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on May&nbsp;12, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465916138978/a16-16617_1ex1d1.htm">Sales Agreement, dated as of August&nbsp;11, 2016, by and between the Registrant and Cowen and Company,&nbsp;LLC
(incorporated by reference to Exhibit&nbsp;1.1 to the Registrant's Current Report on Form&nbsp;8-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on August&nbsp;11, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000110465917062168/a17-23934_3ex1d1.htm">Sales Agreement, dated as of October&nbsp;13, 2017, by and between the Registrant and Cowen and Company,&nbsp;LLC
(incorporated by reference to Exhibit&nbsp;1.1 to the Registrant's Current Report on Form&nbsp;8-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on October&nbsp;13, 2017)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1454789/000104746916011175/a2227770zex-21_1.htm">Subsidiaries of the Registrant (incorporated by reference to Exhibit&nbsp;21.1 to the Registrant's Annual Report on
Form&nbsp;10-K (File No.&nbsp;001-37467) filed with the Securities and Exchange Commission on March&nbsp;15, 2016)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="a2235913zex-23_1.htm">Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP (included in Exhibit&nbsp;5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="#sig">Power of Attorney (contained on the signature page to this Registration Statement)</A></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="23%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="23%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>To
be filed by amendment. </FONT></DD></DL>
 </DIV>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49601_item_17._undertakings."> </A>
<A NAME="toc_ja49601_7"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The undersigned registrant hereby undertakes: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act");
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration </FONT></DD></DL>
</DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=58,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=368330,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the "Commission") pursuant to
Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&nbsp;percent change in the maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective registration statement; and  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such
information in this registration statement.
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2> offering
thereof.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That,
for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and
will be considered to offer or sell such securities to such purchaser:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities
provided by or on behalf of the undersigned registrant; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933
shall be deemed to be part of this registration statement as of the time it was declared effective; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=59,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=131058,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue. </FONT></P>

</UL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=60,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=872256,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JA49601A.;25',USER='HYUNG',CD=';4-JUN-2018;10:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> <A NAME="sig"></A>SIGNATURES  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 4<SUP>th</SUP> day of June, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="279pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>Catabasis Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JILL C. MILNE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jill C. Milne<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc49601_signatures_and_power_of_attorney"> </A>
<A NAME="toc_jc49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>SIGNATURES AND POWER OF ATTORNEY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We, the undersigned officers and directors of Catabasis Pharmaceuticals,&nbsp;Inc., hereby severally constitute and appoint Jill C. Milne and Deirdre A.
Cunnane, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them
for her and in her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration
statement for the same offering that is to be effective upon filing pursuant to Rule&nbsp;462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and
every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as she might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents or any of them, or their or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;JILL C. MILNE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jill C. Milne</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;DEIRDRE CUNNANE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Deirdre Cunnane</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Legal Officer and Treasurer (Principal Financial Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;NOAH CLAUSER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Noah Clauser</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Vice President of Finance and Controller (Principal Accounting Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;MICHAEL ROSS<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Ross</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Co-Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=61,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=254733,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JC49601A.;12',USER='HYUNG',CD=';4-JUN-2018;10:42' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;KENNETH BATE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Kenneth Bate</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Co-Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;BURT ADELMAN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Burt Adelman</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JEAN GEORGE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jean George</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;MICHAEL KISHBAUCH<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Kishbauch</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;4, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=62,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=322892,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]JC49601A.;12',USER='HYUNG',CD=';4-JUN-2018;10:42' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>a2235913zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZBT49601_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg49601_exhibit_23.1"> </A>
<A NAME="toc_kg49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kg49601_consent_of_independent__kg402322"> </A>
<A NAME="toc_kg49601_2"> </A></FONT> <FONT SIZE=3><B>  Consent of Independent Registered Public Accounting Firm  <BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form&nbsp;S-1) and related Prospectus of
Catabasis Pharmaceuticals,&nbsp;Inc. for the registration of common units, pre-funded units and shares of common stock issuable upon exercise of warrants included in such common units and pre-funded
units and to the incorporation by reference therein of our report dated March&nbsp;15, 2018, with respect to the consolidated financial statements of Catabasis Pharmaceuticals,&nbsp;Inc. included
in its Annual Report (Form&nbsp;10-K) for the year ended December&nbsp;31, 2017, filed with the Securities and Exchange Commission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
Ernst&nbsp;&amp; Young&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Boston,
Massachusetts<BR>
June&nbsp;1, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=392646,FOLIO='blank',FILE='DISK103:[18ZBT1.18ZBT49601]KG49601A.;3',USER='CHE105948',CD=';3-JUN-2018;23:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZBT49601_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg49601_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg49601_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=HYUNG,SEQ=,EFW="2235913",CP="CATABASIS PHARMACEUTICALS, INC",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g645187.jpg
<DESCRIPTION>G645187.JPG
<TEXT>
begin 644 g645187.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!)35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=0T%404)!4TE37TY%5S%?-$-?3$]'
M3RY%4%/_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1"  K +T# 2(  A$! Q$!_\0 '@   @(# 0$! 0
M      H'"P(("08% 03_Q  S$  !! ,  0($! 8" @,    % P0&!P$"" D
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M2HMU:H4L;D@<G*@EXYVU]D%TQ?M5@5 ?EQ)!!YW._%8<WB3]<<>7C1Y[.X8
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MVN\9*0%,K0PR2?W:IK;.<:_O_?VQC&<YS[8]\^V,>^<Y]OO[8QG/K'"FN?\
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MX^WL!U38(V[>#];09RQW8Q&3Q!.,"QFIW:#D*KE#<B\);QO!./(CUCC87:Z
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M+=TW1(H,#S$@T1?HMW3I!)XFCJY31<N$M%<)K*:[?U#H;#Q,,2A(J)QD9"T
MZP5"'C@(IE%40RZ:J2X=..MFB0?04LDLJFL.U9X9JIJJ:;H[:[[8RI54!Y'Y
MU\.Y<G&H2T^'H%='/'>IS]"NRU!Q]O8#JFP1MV\'ZV@SECNQB,GB"<8%C-3N
MT'(57*&Y%X2WC>"<>1'K'&PM[+X:"(]%P_P]\UC>A$9@Q-.W]A&JT$SM9YF2
MB:1+2Y^ZK1HJ@5UP48!' [9V5AX]]OO]-#B0' _5N'V&M&_401PSQ+'BPZ1
M..>50<@$/D"@DZ(YXJ$:8%DVZN%VY$<390]%ZR?H+?QD7;99)PDK_$34UW^_
4K;?&,8^V/_W_ -YS]\_[]*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g525311.jpg
<DESCRIPTION>G525311.JPG
<TEXT>
begin 644 g525311.jpg
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MG9]'J*G=WTXSJWZU:6AEO.[4EC+U94";6QZR?&/'(A(:N8'QI9W-T=&XY&.
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MT*W0[4IO>DYA<AD-P3AAVZ5R@CKI7I3)#+0M3&?OZQ.XK8P,:GTW=V1>S;A
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M4KH]$ETZ&72^1=M[F >(S2O #LB(>F!]#4L>B4*< 1#R+EP#P'AQ\>=><![
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M\OKR/1,M,8\..UBY.S^S:M_^(UJ 9<X]L>_J49YWU?>UG[+\=^VH_P#36_\
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MGEZB("(=B>U;YW_S>M([5K-^2Y_1#I%C.(,3JF4Y#^:C'J45?GVJQJ-5*W*
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MAPK? _->U ?K,;[^Z'4W_%:]&]%Z[?B\0'+9E?8AEQ .-@U-Z #YRL1\_O\
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MG4Q.<JDFJF*)H=(H.V*ICG*L)DWJ'AB6L2)J$3G%"<RI%3R<J+^-2MJ8]0:
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MR:L9Y3*UL/<3&>1HXQ!9%-&>8R!6VN)!B;).U,RHU1D "EP/ZH4!F(6?F_\
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MA,ZOD.=SJX20P!9%:9BQ>&-#@L=&R>3YMECC[OO!7'W'5]%[GK0IPPG;O?\
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M&IH$_:4;:BD+HBCB\F3 S,.*DY[CR=L>E2,&_ 6I2O,;<S3C$N>>M?KH5?\
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MQOMJMU;09AB5(0&Y<9DR9PH]!3[U.L;+\<52V,QQ+<%<S@Z.=3)H,G='603
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M\QEVM6%YCSCUU-#[U_\ #^VJ;//,21XY9#V.'9R$>P.0<0Y^8> <0]H/0U2
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MZ02HE,2X^,N- 7@U&$1TTU2A%N!%GF<L+2* 69J2L2,B"RC<E2ZZW">H5/\
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M#CY&O:Q]MN#PXUW9[E6V8YV-KQX_#[7_ ,GTRKAOX4MCOMZ?_23?LK?XT:T
M!Z+9WL@(AY&K:OV!X?);@\.->LNBV-[ !_8U[6./9[ FW!WPG'?U@W<NVQ4
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MI%V=GZO;BKFNH$F@LW5SFTD:>)20$\.<LEBB/E25&VBO3')W!P'#+ O7S/\
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MU(ZQN4-K&])LPSM_J5N7OU>2=2=7D3=(TS-E<M*XQ4XQ",H$$<3O"MK:V@E
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M$G$,.(((X=\Y\P?YCL/3_P#G*2ZF9\[S^QR^#4W LS@/QF?/^IR]KVM=6?\
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MB%P2)U)92@DT@S,H,#RC2AS+R?$:\\S6Y 89D.69B))GGD/ !RSS3%999"
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MNSD7]U5M[<-M^WV&U90U3HJ,#<%NR7J)G;\GW#!(]QEER;Q58-K)DGE3-&9
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M;"%J9O69N\7ZJD)<\2 7EE=+%,<!!2"5.&8YX9Y!U+ 2QP'B(SE'+;<K-C@
MX[^-P.(], <0=XKS<,O1B0^AIL'+S&/U.\.J)5\CQ^C#[W+5/P;AVI?<-IY6
M7P>+D0?N.P5.^,XL)E'A&\RR7AOY".*CH)R^G;3H./+<\K0(\!W];@N;U7B?
MM?L0U,#EM^5G[(^3ZW!CP#CP\5XGP'L@'9X1 !\_T=-78<X]KWPU.#FR[7OA
MKR;#<. .5C:#(KE[GBZU^XJW'B^*$-G?W7DR?7G^03U]8%.F>7<<K/\ K^-P
M/NO%O!+5*=RW7*TAGPQW][@\0X!V =XIP\_L]F(B/\.FO-4AWFQ[0:H^#[#[
M2M?^1%_VUC:8QBC2D-B%T1H)R,S]8[:=)\N[Y6O]?[N$]UXGX(:CY=WRM7Z_
MS<'[KQ3P1TUAHU#)86(U96=L,AT01]7S:V=UBF(I!&RWMR"73,B5\SFI)Z>D
M@4Z*IY;_ )6W#I.EW^[A,>/3<>#O$_.Z7ASQ ?1'5+Y>#RN'_P#D W"^Z\2\
M#]-<*_[G_G_[NJ/4;6%ENT/>EMF2<SN8\SD3EQT]%2VN*8BT2DWMP2=69,C$
M\&&7/JIU<.6^Y6\0 ?+ -PW9 /\ "\1\#M>@Y;_E;@_[?VX4?;%WB?O1  _@
MTU;CS!V@[VHZHO9VF0]RV_/HAC'1V+V"K-YB6(+;HRWDX8LF9$ASXJ3ZQG3O
M=>\LYRJ,TL" Q"5;ZKZ?(S*9[!X[(69<[1@4;LQO4M96UV;%8$Q4DX4J] I4
M)%&)1Q6>1)V>.)F(CQ#K;)<,"TY)9>(8X%E%888AS8X8%88XXA[0   'M!KB
M)4M\V2HOIK5G_MU']=J!@<K<.M*8M;[%H4CIM'$X:J@DM;Y2Z+)R]2]8:[X3
M1HD,2.9"&IG9V=.G9365U2/JX]SS7*2STA(D9=2Y+:)(8);-8X@F\$JG=1\,
MP 09"@R50%(#-D,RJ@YL >MV0O)YX+HW$DT[&YBC1B&DT9Q2.2Q (C3Q2-39
M+J*KGJ9053X\/1^L(]X-1UKV;T)4V9<I;(8K:=MH(76+7M;VIOD48)KRC&ZC
M8TP!(7V\-SB&QG>"1N@BS(W;DL6L+#"D<B*EYK<:UDM\/;168MCXH.2_#2CE
M1=RS4_S2/.EC;?JUAS!NPI7;Y#+UEU92W&&V32ELW#<D3?-US1C)IC"XX3&(
M3G"VZA11-TJ?(WC:<*DUPO#Z;5=G5:Q*=!7:ULF:-:M$8Y13=,DL0^16!;L
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MA9>_'YC>M:E:-&C4$G-O-^JMM>?!HOGQ_FFJ-7_<_P#/_P!W5'JL5_W/_/\
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M&,FJ^=QVRH,Y@J9EK>M 62:11A>02]<=9KQ0 A<TZQN4*DAV'THY+?9;*AB
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MA/ >&L._W4=<]M;]2VTG;@6*@><V,^0K1PRYQ[8]_4W#S(?5[XZJ!;7'B/\
M0]?SC_>*OT?VC4W%N<.E#_H"_P _^\5?MC\X]#LZ^SG9<QXR\NL=?_Z/2*^,
MM#_);_*?V59<N<>V/?U[,\[ZOO:J1;G#B/\ T!=SC_>2OT?VG4S-M<.Q_P!
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M(<>GZ>L>FK5Z";9  <]4?0?DG]H](K[>EOFR5%]-:L_]NH_KMWD_(L/H"_\
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M-G[H<,#>4*Y,S$S#'/ 0WLAECGB&0"&5"Q[#(!QR 0R#+#++$0X" XY98CQ
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M/RYIF>L_3]P]%,AU#T"J*6-K=C=50AB@1 &4:M3I@ZS3AQ_Z/$@^<\>;+(.
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MNQ8BVG/![(:@#PGGZ<OVUUX_++.3N'FWU[01_P#,94OA7H\LMY.[]?7M!_\
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B ,'T/TM&E*-&C1I2C1HT:4HT:-&E*-&C1I2C1HT:4K__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
